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vABSTRACT
Cocaine (COC) is frequently misused with other substances; among them, the most
prominent are ethanol (EtOH), heroin (HER) or its metabolite morphine (MOR), and 3,4-
methylenedioxymethamphetamine (ecstasy or MDMA). Cardiac and hepatic toxicity are
ominous complications of these drugs in humans, and may be further aggravated by their
combination. So, in the current work we sought to assess the hepatotoxic and cardiotoxic
mixture effects of COC combined with EtOH, HER/ MOR, or MDMA.
For this purpose, COC was combined with HER/MOR (Mix A/ Mix B), EtOH (Mix C)
or MDMA (Mix D) at the same drug ratio found in the blood of intoxicated abusers or in
seized ecstasy pills. Then, primary cultured hepatocytes isolated from Wistar Han rats and
H9c2 rat cardiomyocytes were exposed to the individual drugs or their combinations. After
24h, cytotoxicity was recorded and mixture expectations predicted by concentration addition
(CA) and independent action (IA) models. Changes in the intracellular contents of reduced
(GSH) and oxidised (GSSG) glutathione, adenosine triphosphate (ATP), reactive species
of oxygen and nitrogen (ROS/RNS), and in the mitochondrial membrane potential (ΔΨm)
were also evaluated.
Primary hepatocytes were more susceptible than H9c2 cardiomyocytes to the drug-
induced toxicity. HER (EC50 0.26 mM) and MDMA (EC50 1.07 mM) revealed to be the most
toxic drugs, in primary hepatocytes and H9c2 cells, respectively. The toxicity predicted by
CA and IA was roughly coincident; except for Mix C cardiotoxicity, none of the models
predicted mixture effects accurately. This was probably a consequence of alterations on
pharmacokinetics/ dynamics pathways, when drugs were in association. Increased
ROS/RNS and GSSG, depletion of GSH and energetic stores, and mitochondrial
hyperpolarization seemed to be involved in the observed cardiotoxicity.
Overall, the presence of other drugs greatly altered COC individual toxicity as
several synergisms and additive effects were observed. Both occurrences are worrisome
and, in a clinical perspective, may significantly deteriorate the health of abusers. Of concern,
the toxicological impact of the co-occurrence of COC and other substances could be hardly
anticipated by the most broadly employed models for the calculation of mixture effects of
chemicals. Evidence from our work also indicates that the effects of a particular mixture
might not be consistent among distinct organs, suggesting that, depending on the functional
specificity of the target sites, differential mechanisms of toxicity/ protection might be
activated.
Keywords: Cocaine; Heroin/ Morphine; 3,4-Methylenedioxymethamphetamine
(ecstasy, MDMA); Ethanol; In vitro toxicity.
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RESUMO
A cocaína (COC) é frequentemente misturada com outras substâncias, entre estas,
as mais utilizadas são o etanol (EtOH), a heroína (HER) ou o seu metabolito morfina (MOR)
e a 3,4-metilenodioximetanfetamina (ecstasy ou MDMA). A hepatotoxicidade e a
cardiotoxicidade são das complicações mais proeminentes destas drogas em humanos, as
quais podem ser exacerbadas pela combinação destas substâncias. Assim, no presente
trabalho pretendeu-se avaliar os efeitos hepatotóxicos e cardiotóxicos da mistura da COC
com o EtOH, a HER/ MOR, ou a MDMA.
Para este efeito, a COC foi combinada com a HER/MOR (Mix A/ Mix B), o EtOH
(Mix C) ou a MDMA (Mix D) na proporção encontrada no sangue de indivíduos intoxicados
ou em pastilhas de ecstasy apreendidas. De seguida, hepatócitos primários isolados de
ratos Wistar Han e cardiomiócitos de rato H9c2, foram expostos às substâncias
individualmente e em combinação. Após 24h, a citotoxicidade foi avaliada e os efeitos de
mistura previstos pelos modelos de adição concentração (CA) e ação independente (IA).
Alterações a nível do conteúdo intracelular da glutationa reduzida (GSH) e oxidada
(GSSG), da adenosina trifosfato (ATP), das espécies reativas de oxigénio e nitrogénio
(ROS/RNS) e do potencial da membrana mitocondrial (ΔΨm) foram também avaliadas.
Os hepatócitos primários demonstraram ser mais suscetíveis do que o
cardiomiócitos H9c2 à toxicidade induzida por estas substâncias. A HER (EC50 0,26 mM) e
o MDMA (EC50 1,07 mM) revelaram ser as substâncias mais tóxicas, nos hepatócitos
primários e nas células H9c2, respetivamente. Para todas as misturas testadas, a
toxicidade prevista por AC e AI foi praticamente coincidente, à exceção da Mix D, quando
testada em hepatócitos primários. No entanto, nenhum dos modelos conseguiu prever com
precisão os efeitos de mistura observados, provavelmente, uma consequência de
alterações nas vias farmacocinéticas/ dinâmicas destas substâncias, quando
concomitantemente consumidas. O aumento de ROS/RNS e GSSG, a diminuição de GSH
e das reservas energéticas, e hiperpolarização mitocondrial parecem estar envolvidos na
cardiotoxicidade observada.
Em suma, os nossos resultados indicam que a presença de outras substâncias
podem alterar significativamente a toxicidade individual da COC, uma vez que foram
observados vários sinergismos e efeitos aditivos. Estes efeitos são preocupantes e podem
deteriorar significativamente a saúde dos consumidores. Igualmente preocupante é a
dificuldade em antecipar o impacto toxicológico da coadministração da COC e outras
substâncias por modelos que são amplamente utilizados para o cálculo dos efeitos de
misturas. Adicionalmente, o nosso trabalho evidencia que os efeitos de uma mistura podem
não ser consistentes nos diferentes órgãos, o que sugere que a toxicidade pode depender
vii
da especificidade funcional dos locais alvo das substâncias e, consequentemente, da
ativação diferencial de mecanismos (des)toxificantes.
Palavras-chave: Cocaína; Heroína/ Morfina; 3,4-Metilenedioximetanfetamina
(ecstasy, MDMA); Etanol; Toxicidade in vitro.
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1. Introduction
1.1. Cocaine (COC): Historical perspective
Cocaine (COC) or benzoylmethylecognine is a coca alkaloid extracted from the
leaves of Erythroxylon coca plant , which is found in the high mountain ranges of Bolivia,
Colombia, and Peru (Freye & Levy, 2009). Although the modern incarnation of COC only
occurred in the 1860s, coca plant had been cultivated as far back as 3000 BC by indigenous
people from South America, who used to chew the leaves of the plant in magical ceremonies
and initiation rites due to its psychoactive and stimulating properties (Freye & Levy, 2009;
Volkow, 2009). and ancient Incas used its leaves.
In 1859, COC was synthesized for the first time by the German chemist Albert
Nieman. In 1863, Angelo Mariani, a Corsican chemist, created Vin Mariani, a wine product
containing coca leaves extract (unpurified COC). This new tonic achieved success in
Europe and became a drink of choice to famous personalities, such as writers, compositors,
and royal members (Freye & Levy, 2009; Karch, 1999). In 1884, the Austrian
psychoanalysis founder Sigmund Freud published an article about the benefits of the drug;
he was the first defending the healing effects of COC, in cases of depression (Freye & Levy,
2009; Volkow, 2009). In the late nineteenth century, coca extract products were considered
a boon to medicine; they were used as a muscle relaxant, and as remedies to treat
respiratory ailments, such as asthma and whooping cough, in which other medical
treatments wee ineffective. However, with the advantage came the problem and many users
became addicted; for example, some people who used COC to combat morphine (MOR)
dependence became addicted to both (Freye & Levy, 2009).
Later, in 1886, Atlanta introduced legislation against the consumption of alcoholic
beverages and a non-alcoholic version of his popular beverage was developed by
introducing a syrup containing extracts of fruits from the kola and coca leaves, which is
currently known as Coca-Cola. This soft drink is the most popular in history as it produces
euphoric and energizing effects on consumer (Freye & Levy, 2009; Volkow, 2009). Although
the soft drink has kept the same name, nowadays Coca-Cola does not contain COC. In
1904, when the dangers of the drug became more evident, public pressure forced Coca-
Cola Company to remove COC from the beverage. However, there is some evidences that
decocanized coca leaf extracts are still used.
The early twentieth century was marked by an increase in COC consumption,
particularly among labourers, the youth, and the urban underworld; and also by an increase
in the perils associated. In the year of 1912, 5,000 COC-related deaths occurred in the
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United States of America (USA), fomenting calls for prohibition. In 1920, the drug was
officially banned (Freye & Levy, 2009).
In the current century, COC had become the second most trafficked illegal drug in
the world, after cannabis (EMCDDA, 2012).
1.2. Cocaine (COC) trading: presentation forms, routes of administration
and prevalence of consumption
COC is consumed as two different chemical forms, the water-soluble hydrochloride
salt and the water-insoluble COC free base. The choice of one form to the detriment of the
other one depends on the social settings of the users.
The hydrochloride salt, the powder form of COC, is typically snorted or injected. On
the street, it is known as “coke”, “C”, “snow”, “flake” or “blow” and can be diluted with inert
substances, such as talcum powder or sugar, or with active substances, such as procaine,
amphetamine, lidocaine, and opioids (Volkow, 2009). This form of COC is the one clinically
used to promote anaesthesia.
The COC freebase is the smoked form of the drug. The hydrochloride salt is
processed with ammonia or sodium bicarbonate (NaHCO3) and water, and then heated to
remove hydrochloride (EMCDDA, 2007). On the street, COC freebase is denominated as
‘crack’, due to the crackling sound produced when the mixture is smoked (Volkow, 2009).
There is a critical heterogeneity among COC users. It is believed that a high number
of people use COC sporadically (Van der Poel, Rodenburg, Dijkstra, Stoele, & Van de
Mheen, 2009). Only a low number of abusers are addicted users, who inject COC or smoke
crack. They represent an urban phenomenon: most are homeless, unemployed, sex
workers, and heroin (HER) addicts (EMCDDA, 2002). Contrary to these COC heavy users,
who are socially marginalized or belong to disadvantage groups, there are also some
regular users that are individuals integrated in society, who consume COC only at
weekends, parties or other special occasions (EMCDDA, 2012). These users are mainly
males, who snort powder COC and use the drug alone or in combination with cannabis or
ethanol (EtOH).
About 15.5 million Europeans have used COC at least once in a lifetime; 4.6% of
the adults (aged 15-64 years), and 6.3% of the young adults (aged 15-34) (EMCDDA, 2012).
The European countries with higher prevalence of COC abuse among the youth are Spain
(4.4%) and the United Kingdom (4.2%). Not surprisingly, these two countries present
consumption levels similar to Australia (4.8%) and the USA (4.0% among 16-34-year-old
adults) (EMCDDA, 2012). In fact, along with Netherlands, Portugal, and Belgium, these are
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the principal points of entry for COC into Europe, where in 2005 were seized 107 tons of
the drug – half of this amount was apprehended in Spain (EMCDDA, 2007, 2012).
1.3. Pharmacological and toxicological mechanisms of action
1.3.1. Peripheral nervous system
COC acts peripherally as a local anaesthetic mainly by inhibiting sodium influx
through specific ion channels in the neuronal cell membrane, in particular the so-called
voltage-gated sodium channels (Goldstein, DesLauriers, & Burda, 2009).
Following nerve stimulus, the sodium channels present at the neuronal membrane
open, allowing sodium ions to migrate into the cell, causing depolarization. The change on
the voltage difference created between the inside and the outside of the axon needs to be
counteracted, so potassium ions move out of the axon to repolarize the membrane and the
impulse travels down the axon to the terminal, where it signals other neurons. COC has
great affinity to the receptors located at the cytoplasmic portion of the sodium channel, and
is highly effective in preventing them from opening. When the influx of sodium is interrupted,
an action potential cannot arise and the transmission of nerve impulses is blocked (Brown,
Prager, Lee, & Ramsey, 1992; Freye & Levy, 2009; Goldstein et al., 2009; Hollander, 2008).
COC active metabolites, such as norcocaine (NCOC), are also capable of similar interaction
with the sodium channels (Matthews & Collins, 1983).
Of note, COC is the only local anaesthetic that exhibits vasoconstriction properties.
All other synthetic local anaesthetics are usually mixed with a vasoconstrictor to extend the
duration of anaesthesia (Freye & Levy, 2009).
1.3.2. Central nervous system
The central nervous system (CNS) is a main COC target (Goldstein et al., 2009).
Contrarily to other local anaesthetics that elicit CNS depression at low doses and CNS
stimulation at high doses, COC provokes euphoria and alertness at low doses and
aggressiveness, disorientation, and hallucinations at high doses (Goldstein et al., 2009).
COC pharmacological and toxicological effects at the CNS are a consequence of
the high affinity of the drug to the receptors of serotonin (5-HT) and of the catecholamines
noradrenaline (NA) and dopamine (DA) (Carroll et al., 1992; Freye & Levy, 2009; Heard,
Palmer, & Zahniser, 2008). COC impairs the adrenergic and dopaminergic systems by
binding the respective receptors and blocking the reuptake of 5-HT, NA, and DA, this way
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increasing their concentration in the synaptic cleft. For instance, in the dopaminergic
neuron, COC binds to DA transporter (DAT) on the membrane of pre-synaptic neurons,
blocking the removal of DA from the synaptic cleft and its further degradation by monoamine
oxidase (MAO) in the nerve terminal (Caine et al., 2002; Dackis & O'Brien, 2001; Freye &
Levy, 2009; Schilstrom et al., 2006). The DA is then free to bind to its receptors on the post
synaptic membrane, producing further activation of dopaminergic neurons.
The addiction and reward effects of COC might be related with the activation of
serotonergic pathways, but they are mostly a result of excessive dopaminergic activity on
the ventral tegmental area, the nucleus accumbens and the caudate nucleus (Freye & Levy,
2009; Goldstein et al., 2009; Sora et al., 2001). The increased dopaminergic activation of
these areas, known as the reward pathway of the brain, leads to the feeling of euphoria and
the ‘high’ associated with use of the drug. Chronic COC abusers have a lower number of
DA receptors, compared with age- and gender-matched controls. They also have
decreased dopaminergic activity, which results in impairment of the hedonic function
(Dackis & Gold, 1985; Dackis & O'Brien, 2001; Volkow, Fowler, & Wang, 2003; Volkow,
Fowler, Wang, & Swanson, 2004). Drug abusers have, therefore, difficulty to be stimulated
by non-drug-related environmental stimuli (Volkow et al., 2004).
Although COC abusers present a higher amount of DAT, the receptor levels
normalize after interrupting consumption (Malison et al., 1998; Volkow et al., 2004).
1.3.3. Cardiovascular system
COC induce several cardiovascular complications, including myocardial ischemia or
infarction, coronary vasospasm, accelerated coronary atherosclerosis, coronary
thrombosis, and hypertension (Afonso, Mohammad, & Thatai, 2007; Aslibekyan, Levitan, &
Mittleman, 2008; Awtry & Philippides, 2010; Hollander, 2008; Kloner, Hale, Alker, &
Rezkalla, 1992; Restrepo et al., 2009; Satran et al., 2005). The mechanisms underlying
these effects are mainly provoked either by the blockade of sodium channels, or by the
blockade of reuptake of catecholamines in the presynaptic neurons, resulting in a
potentiation of the sympathetic effects.
The sympathomimetic activity of COC at the presynaptic adrenergic terminals leads
to overstimulation of the alpha-adrenergic receptors in the coronary and peripheral arteries.
This effect has several consequences, including vasoconstriction, increased coronary
resistance, and decreased coronary blood flow, elevated blood pressure (BP), and
increased myocardial wall stress.
COC also blocks the voltage-gated sodium channels in the myocardium, altering the
generation and conduction of the action potential and, consequently, extending the PR, QT
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and QRS intervals. Despite concomitant sympathomimetic stimulation, these occurrences
are responsible for the COC negative inotropic effect (Afonso et al., 2007; Goldstein et al.,
2009; Kloner et al., 1992; O'Leary & Hancox, 2010; Restrepo et al., 2009). Additionally,
elevated intracellular calcium concentration in the myocyte are also responsible for the
development of cardiac dysrhythmias (Bauman, Grawe, Winecoff, & Hariman, 1994;
Hollander, 2008; Restrepo et al., 2009).
1.3.4. Liver
COC is bioactivated through metabolism into reactive prooxidant metabolites, which
are highly deleterious to the structural and functional integrity of the cell (for more details,
see the section ‘1.4.2 Metabolism’). Due to its relevant role on the metabolism of
xenobiotics, the liver is therefore a target organ for the toxicity of the drug (Goldstein et al.,
2009; Ndikum-Moffor, Schoeb, & Roberts, 1998). Accordingly, the hepatotoxicity promoted
by COC is dose- and time-dependent, and directly correlated with cytochrome P450 (CYP
450)  activity and the levels of NCOC (Smith, Freeman, & Harbison, 1981).
The hepatic effects of the drug were first observed by Ehrlich et al. (1890), in the
mice liver. Later, Marks and Chapple (1967) reported the drug hepatotoxicity also in humans
by observing abnormal liver test results in HER and COC addicts. In 1987, Perino and
collaborators linked these clinical findings to liver necrosis (Perino, Warren, & Levine, 1987).
After that, several studies were made and results demonstrate significant necrosis in
centrolobular hepatocytes, where the levels of CYP 450 are higher (Kanel, Cassidy,
Shuster, & Reynolds, 1990), suggesting a role for metabolism in the toxicity of COC.
1.4. Toxicokinetics
As aforementioned, COC might be consumed as a freebase or as a salt. This aspect
will significantly impact the pharmacokinetic properties of the drug (Freye & Levy, 2009;
Goldstein et al., 2009).
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1.4.1. Absorption and distribution
The administration route plays a major role in the bioavailability, intensity and
duration of the elicited effects of the drug (Hatsukami & Fischman, 1996). While COC
hydrochloride is snorted or intravenously injected, the freebase form (crack) is smoked.
COC bioavailability is total when the drug is intravenously administered. The other
administration routes (nasal inhalation and smoking) allow the drug to be rapidly absorbed,
with a bioavailability of approximately 90% for smoked COC. When the drug is snorted, the
bioavailability is dose-dependent and ranges from 25 to 94% (Freye & Levy, 2009;
Goldstein et al., 2009; Hatsukami & Fischman, 1996; Heard et al., 2008). The bioavailability
of COC per os is about 30% (Goldstein et al., 2009; Hatsukami & Fischman, 1996).
COC effects are sensed 7-10 seconds after smoking, as the drug is quickly absorbed
through the extensive network of pulmonary capillaries. Therefore, crack has great
popularity due to the rapid onset of its euphoric effects. Similarly, COC effects are almost
instantaneously sensed after i.v. administration (30-45 seconds after administration)
(Glauser & Queen, 2007; Tashkin, Kleerup, Koyal, Marques, & Goldman, 1996). The
intranasal (i.n.) administration takes roughly 3-5 minutes to exert effect, while oral ingestion
produces effects only 15 minutes after intake (absorption is slower) (Freye & Levy, 2009).
The smoked form of COC is very dangerous because the time needed to peak
subjective effects is very short. Also, the peak plasma concentration is reached within few
minutes of the dose administration (approximately 5 minutes later) (Hatsukami & Fischman,
1996). The absorption kinetic of COC is similar for i.v. injected COC hydrochloride and
smoked crack COC (Hatsukami & Fischman, 1996).
After absorption, the distribution is rapid and the drug spreads to several organs.
COC reaches the highest concentrations in brain, spleen, kidney and lung, followed by
heart, blood and muscle (Bortolotti, Gottardo, Pascali, & Tagliaro, 2012). In humans, the
volume of distribution fluctuates from 1.96 to 2.7 L/Kg (Goldstein et al., 2009; Jeffcoat,
Perez-Reyes, Hill, Sadler, & Cook, 1989). After the administration of an i.n. dose of 20 mg,
COC could be detected in the serum during 4-6 h; after a 100 mg administration, the drug
remained in the serum at least for 12 h (Maurer, Sauer, & Theobald, 2006).
There is evidence that the bioavailability of COC is impacted by gender and,
therefore, several studies were made to scrutinize the effects of sex hormones and of
menstrual cycle on COC serum concentrations (Lukas et al., 1996). Studies demonstrated
that male rats present peak COC concentrations around 50% higher than those found in
females following i.v. administrations (Festa et al., 2004; Heard et al., 2008; Kosten et al.,
1996).
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1.4.2. Metabolism
COC is rapidly metabolized by multiple enzymatic pathways (Figure 1). ). The major
metabolites are benzoylecgonine (BE) and ecgonine methyl ester (EME), both metabolized
to ecgonine (Bortolotti et al., 2012; Goldstein et al., 2009; Valente, Carvalho, Bastos, de
Pinho, & Carvalho, 2012). The metabolite BE results from the enzymatic hydrolysis by
human carboxylesterase type 1 (hCE1) in human liver, and represents nearly half of the
absorbed dose; while EME may be formed when COC is metabolized by human
carboxylesterase type 2 (hCE2) or by pseudocholinesterase (PChE). As EME has low
pharmacological effects, individuals presenting low PChE activity sense the effects of COC
for longer periods (Bortolotti et al., 2012; Goldstein et al., 2009; Valente et al., 2012). N-
demethylation of COC by CYP450 produces NCOC, a minor metabolite. This metabolite
represents 5% of the absorbed drug and crosses the blood-brain barrier (BBB) to produce
clinical effects identical to those of COC. The metabolites EME and BE are unable to cross
the BBB and, consequently, of exerting effects at the CNS (Goldstein et al., 2009).
Figure 1. Cocaine metabolism. BE – benzoylecgonine; CE – cocaethylene; ED – ecgonidine; EDEE –
ecgonidine ethyl ester; EDME – ecgonidine methyl ester; EEE – ecgonine ethyl ester; EME – ecgonine methyl
ester; hCE1 – human carboxylesterase type 1; hCE2 – human carboxylesterase type 2; NBE –
norbenzoylecgonine; NCE – norcocaethylene; NCOC – norcocaine; NEDME – norecgonidine methyl ester;
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NEME – norecgonine methyl ester; OH-BE – hydroxybenzoylecgonine; OH-COC – hydroxycocaine; PChE –
pseudocholinesterase. Adapted from Valente et al. (2012).
The oxidation of NCOC by CYP450 originates N-OH-NCOC, which by turn is
metabolized to the free radical NCOC-NO., in the presence of a nicotinamide adenine
dinucleotide phosphate (NADPH)-generating system (Pellinen et al., 2000). Studies in vitro
demonstrated the involvement of NCOC metabolism in COC hepatotoxicity. Two different
mechanisms may be at a play. On the one hand, it has been suggested that NCOC-NO.
enters in a redox cycle, as it can be reduced to N-OH-NCOC by flavoproteins and,
consequently, oxidized to NCOC-NO. by CYP450. This redox cycle can be responsible for
the production of reactive species of oxygen (ROS), causing hepatotoxicity via mechanisms
of oxidative stress, involving lipid peroxidation (Boelsterli & Goldlin, 1991; Valente et al.,
2012). On the other hand, COC-induced hepatotoxicity may involve oxidation of NCOC-NO.
to NCOC nitrosonium, a highly reactive compound that binds to hepatic proteins, leading to
impairment of the hepatocellular function (Charkoudian & Shuster, 1985). A study made by
Ndikum-Moffor et al. (1998) presented results consistent with these two mechanisms. By
using P450 inhibitors, the authors proved the importance of CYP450 on COC toxicity, as it
was responsible for oxidizing N-OH-NCOC to NCOC-NO. and for oxidizing the nitroxide to
other reactive species.
Anhydroecgonine methyl ester (AEME) is a metabolite formed when COC is smoked
(Figure 1). It can be detected and quantified in different biological fluids, such as urine,
sweat and hair; and produces muscarinic effects on the cardiovascular system (Goldstein
et al., 2009; Kintz, Sengler, Cirimele, & Mangin, 1997). This pyrolysis end product is
transformed in ecgonidine (ED) via esterase activity (Bortolotti et al., 2012; Caplan, 2015).
Along with AEME, ED is used as a biomarker of crack smoking (Cone, Hillsgrove, & Darwin,
1994).
The co-administration of COC and EtOH results in ethylbenzoylecgonine or
cocaethylene (CE) (Figure 1), a product formed by hCE1-mediated transesterification of
these two drugs in liver (Bortolotti et al., 2012; Goldstein et al., 2009). A study demonstrated
that 17% of i.v. COC was converted to CE, an active metabolite with a longer half-life (t1/2)
than COC (1.7 h and 0.7 h, respectively). Additionally, compared to COC, CE presents
higher euphorigenic and reinforcing properties (Bortolotti et al., 2012; Goldstein et al.,
2009). This metabolite is an important biomarker of COC and EtOH co-administration and
it can be quantified in urine (Politi, Zucchella, Morini, Stramesi, & Polettini, 2007).
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The co-administration of crack and EtOH leads to the formation of anhydroecgonine
ethylester (AEEE), which can be used as a biomarker of the co-exposure to these two drugs
(Myers, Williams, Kraner, & Callery, 2005).
1.4.3. Excretion
COC is mainly excreted in urine, after metabolism; a minor percentage of the drug
is excreted in faeces. Approximately 9.5-20% of unchanged COC is eliminated in urine and
may be detected 24-36 h after consumption. The major metabolites eliminated in urine are
EME (32-49%) and BE (35-54%) and can be detected up to 24 h. Along with ecgonine,
these metabolites represent 80-90% of urinary metabolites in humans (Bortolotti et al.,
2012; Goldstein et al., 2009).
Research conducted to unveil the disposition and elimination pathways of COC after
repeated administration demonstrated that the drug and its metabolites have a biphasic
excretion profile. Following the drug withdrawal, an initial elimination phase is immediately
observed, presenting an elimination pattern comparable to that observed after acute dosing.
A second, long-term elimination phase occurs during abstinence, as a result of a protracted
release of COC accumulated in the body. Although the concentrations of COC and
metabolites detected in this terminal phase are fairly low, the t1/2 of parent compound and
metabolites greatly exceed the t1/2 reported for the first phase and those observed in
previous studies on acute COC administration, enabling the drug to be detected in saliva
and urine for an extended period after long-term, high-dose administrations (Jufer, Wstadik,
Walsh, Levine, & Cone, 2000).
Also with the intent of evaluating the pharmacokinetics of chronic COC
administration, Jufer et al. (2000) performed a study in healthy volunteers who were given
ascending oral doses of COC (from an initial intake of 500 mg/day up to 2 g/day). The
authors reported mean plasma, saliva and urine COC elimination t1/2 of 1.5 h, 1.2 h and
4.1 h, respectively, for the first elimination phase. These values were mostly similar to those
observed for COC elimination t1/2 after acute dosing. In 50% of the tested subjects, the
second elimination t1/2 for COC was 19h. It is possible that a biphasic elimination profile
was also present for the remaining subjects, but it was difficult to confirm the existence of a
second elimination phase due to the interference caused by high concentrations of BE that
obfuscated COC quantification. During the terminal elimination phase, the urinary t1/2 of
metabolites were estimated to range from 14.6 to 52.4 h (t1/2 substantially longer than
previously estimated). This biphasic elimination pattern for COC and its metabolites
suggests that the drug accumulates in the body during chronic exposure.
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As a lipophilic drug, COC is likely to be deposited in the adipose tissues, where it
has already been detected in post-mortem cases of COC poisoning (Jufer et al., 2000;
Moolchan, Cone, Wstadik, Huestis, & Preston, 2000). Additionally, detection of COC and
its metabolites can be performed on several other biological specimens, such as hair,
sweat, meconium, saliva, and amniotic fluid.
1.5. Polydrug abuse
. As a club drug, COC use is linked with simultaneous consumption of other illicit
and licit drugs, such HER and EtOH. This polydrug abuse pattern is intended to increase or
modify the psychoactive effects of the drug, to leaven or compensate for its negative effects
and/or to supplement for it when supply is low (Kelly & Parsons, 2008). According to Pakula
et al. (2009), the combined use of COC might be instigated by circumstantial and functional
reasons (Figure 2).
In circumstantial models, the choice of combining different drugs depends on
environmental constraints and influences, while in functional models the consumer chooses
substances based on aims or expectancies (Pakula, Macdonald, & Stockwell, 2009). Often,
the selection of the drug combination is based on descriptions made by other users on the
duration and on the subjective effects perceived during pleasurable drug experiences
(EMCDDA, 2002). However, individual characteristics or environmental and social factors
may severely impact the pharmacological and toxicological effects of the drugs. In addition,
as a specific substance may interact with the body in a different and completely
Functional/ strategic motivation
•Pharmacological
To achieve a unique set of effects;
To achieve a greater positive effect;
To achieve a prolonged effect;
To ease withdrawal; To relieve/ reduce
unwanted effects.
•Social
To enhance social relationships and
occasional experiences.
•Economic
A complement or substitute becomes
cheaper or more readily available.
Circumstancial/ non-strategic
motivation
•Opportunistic/ environmental
Patterns of emergence and exposure.
•Social
The prohibition of drugs through
sumptuary legislation or religious law; A
drug use pattern is firmly entrenched in
a subculture of users;
Peer influences.
•Economic
Substituition due to price and
availability, without consideration for a
drug interaction.
Figure 2.  A conceptual model for understanding the reasons underlying polydrug abuse. Adapted from Pakula
et al. (2009).
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unpredictable way when it is in the presence of other drugs, polydrug abuse is frequently
related to health-threatening drug reactions (EMCDDA, 2002; Kelly & Parsons, 2008).
Also, the choice of co-misused psychoactive substances depends on local
availability, personal preferences, fashion, and other factors (EMCDDA, 2009). Cannabis
and EtOH are the substances most combined with COC. In 2003, the European School
Survey Project on Alcohol and Other Drugs (ESPAD) demonstrated high-prevalence rates
of COC co-use with cannabis, among young students (15 to 16 years old) (EMCDDA, 2009;
Olszewski, Matias, Monshouwer, & Kokkevi, 2009). Opiates and tobacco are also frequently
co-consumed with the drug (Pakula, Macdonald, & Stockwell, 2009). In some countries, 67-
89% of COC users have consumed cannabis concomitantly, while more than 60% have
used amphetamines (50% have used ecstasy). On the other hand, co-consumption of EtOH
is practiced by 14-58% of COC users (Table 1) (EMCDDA, 2009).
Table 1 Prevalence of drugs used among cocaine abusers. Data are presented as the mean of results from 33
European countries. Adapted from EMCDDA (2009).
Co-abused drug Prevalence of use (%)
Cannabis 65.1
Ecstasy 53.6
Heroin 40.7
Amphetamines 35.6
Hallucinogenic mushrooms 35.3
LSD 35.0
It is possible that polydrug misuse is influenced by gender, as studies demonstrated
higher prevalence among young males. On the other hand, no significant relationship was
established between polydrug abuse and the mental health condition of the abuser (Table
2) (Kelly & Parsons, 2008).
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Table 2. Relationship between polydrug abuse and mental health condition of abusers (n=361). The values
represent the odd ratios. Adapted from Kelly et al. (2008)
Mental disorder Polydrug users Non-polydrug users
Depression 0.87 0.91
Anxiety 0.78 0.85
Stress 2.70 2.55
Coping ability 3.68 3.65
Problem drinking 12.49 13.64
1.5.1. Cocaine (COC) and ethanol (EtOH) co-use
Some studies indicate that up to 90% of COC abusers also consume EtOH (Czoty,
2015; Helzer & Pryzbeck, 1988; Kampman et al., 2013). The use of EtOH with COC is
considered dangerous, as the combination can be more cardiotoxic and hepatotoxic than
EtOH or COC alone (EMCDDA, 2002). EtOH induces CYP 450 and its chronic use is
capable of potentiating COC-induced liver damage (e.g., severe centrolobular hepatic
necrosis) (Smith et al., 1981). Concomitant use of COC and EtOH increases levels of COC
in blood (about 30%) and produces CE, a metabolite with longer t1/2 (Bortolotti et al., 2012).
Pharmacological and physiological effects of CE and COC are similar; these two
substances increase dopaminergic activity by activating mesolimbic pathways. In nucleus
accumbens, it was shown that both COC and CE block DA reuptake, resulting in increased
extracellular levels of DA (Czoty, 2015; Sobel & Riley, 1999). As these substances increase
BP and heart rate (HR), they can increase EtOH consumption by masking EtOH intoxication
effects (EMCDDA, 2009; Farre et al., 1997). In humans, administration of COC following
EtOH intake decreases BE levels in urine, whereas increases CE levels (Harris, Everhart,
Mendelson, & Jones, 2003).
The mechanisms of interaction of CE with COC or with EtOH are yet to be
completely disclosed, but some authors claim that in humans the interaction with COC is
additive; CE can be transesterified to COC, in the presence of methanol, by hepatic
esterases, which results in increased levels of COC, prolonging the action the parent drug
(Bailey, 1994). Therefore, the dose addition effect reported for CE with COC and for CE
with EtOH could help explain the higher physiological and pharmacological effects
observed, compared to the consumption of EtOH or COC alone.
A further study conducted in rats aimed to analyse the behavioural interactions of
CE with COC and with EtOH on schedule-controlled responding. The authors used drug-
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experienced rats that were previously administered CE, COC, and EtOH alone, and
measured the rate of drug licking. Then, they combined CE with COC or with EtOH and
demonstrated that the dose-response curves for COC and EtOH alone were shifted to the
left and down by the presence of CE. Also the CE curve was displaced to left and down by
both COC and EtOH (Figure 3 and 4). These results confirmed that CE interacts with EtOH
and with COC, increasing the effect of the individual drugs (Sobel & Riley, 1999). The
authors argued for the occurrence of an additive interaction underlying the effects observed
for the mixture of CE with COC or with EtOH, as the isobolographic analysis revealed that
the ED50 values for the combinations CE–EtOH and CE–COC did not significantly differ
from the additive calculations, suggesting that these two drugs work by a common
mechanism (Sobel & Riley, 1999).
Figure 3. Dose-response relationships for cocaine (top) and ethanol (bottom) administered alone or in
combination with cocaethylene. Statistically significant differences (p<0.05) were observed between the
individual and combined administrations for all doses tested (5.6; 10; 18 mg/kg). Retrieved from Sobel & Riley
(1999).
PART I: INTRODUCTION
15
The co-administration of COC with EtOH has been involved in several fatalities
(Pilgrim, Woodford, & Drummer, 2013) and the cardiovascular toxicity that arise from this
combination was implicated in the cause of the majority of these deaths (Garfia, Valverde,
Borondo, Candenas, & Lucena, 1990). The co-administration of COC and EtOH is
particularly dangerous because these drugs activate the sympathetic nervous system
through the increase of catecholamines, consequently increasing HR and BP (Garfia et al.,
1990). In Table 3 are compiled results from a few studies performed to evaluate the
consequences of EtOH intake on COC pharmacokinetics.
Figure 4 Dose-response relationships for cocaethylene administered alone and in combination with cocaine
(top) and ethanol (bottom). Statistically significant differences (p<0.05) were observed between the individual
and combined administrations of cocaine (5.6 mg/kg and 10 mg/kg) for all doses tested of cocaethylene (5.6;
10; 18 mg/kg). Statistically significant differences (p<0.05) between the individual and combined administrations
of 0.75 g/kg ethanol were observed for all doses tested of cocaethylene (5.6; 10; 18 mg/kg) and for
administrations of 0.56 g/kg ethanol with 18 mg/kg cocaethylene. Retrieved from Sobel & Riley (1999).
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In opposition to EtOH administration, which is ingested per os, different forms and
routes of administering COC are used, as already mentioned (Pakula, Macdonald, &
Stockwell, 2009). A study made by Gossop et al. (2006) demonstrated differences in the
effects attained when smoking crack or snorting COC with EtOH. Crack users drink less
EtOH at the end of crack-using sessions, while users who insufflate COC take increased
doses of the drug and EtOH. These differences can be related to the different impact of the
administration route on the pharmacokinetics of the drug (absorption and bioavailability)
and on the balance of euphoric/ dysphoric effects. In general, EtOH is often used when
COC is snorted (Pakula, Macdonald, Stockwell, & Sharma, 2009), and these users are more
susceptible to heavy drinking and to serious adverse effects than crack abusers (Gossop
et al., 2006). Snorting COC along with EtOH intake may result in a vicious cycle that
ultimately ends up in high consumption of both drugs, as described in a testimony published
by Pakula et al. (2009):
“If you drink, you get depressed. Then you do line, you get happy and then if you did
too much lines and not enough drinking then you’d be off the wall and everyone would know
you are screwed up (…). Up down up down up down you can’t find a balance which you
never find.
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Table 3. Studies in volunteers on the co-use of cocaine (COC) and ethanol (EtOH). Blood pressure (BP); cocaethylene (CE); Intanasal (i.n.); Intravenous (i.v.); Hert rate (HR);
Volume of distribution (VD).
Number
of
subjects
studied
COC dose
(route of
administratio
n)
EtOH dose
(route of
administrati
on)
CE dose
(route of
administratio
n)
Mean peak values Mixture effects (compared
with COC and EtOH alone)
Reference
9 100 mg (i.n.) 1 g/kg (oral) Higher COC plasma levels;
Increased HR and BP.
(Farre et al., 1993)
12 After 50
minutes of
EtOH
ingestion was
given 1.25
mg/kg (i.n.) or
1.9 mg/kg (i.n.)
0.85 g/kg
administered
over a 30
minutes
period
EtOH blood concentration:
0.092 g/dL;
COC plasm concentration:
10.48 (ng/mL);
CE plasm concentration:
15.44 (ng/mL).
Increased COC plasm
concentration;
Increased HR.
(Perez-Reyes &
Jeffcoat, 1992)
3 0.25 mg/kg
(i.v.)
0.25 mg/kg
(i.v.)
- Tachycardia. (Perez-Reyes,
1993)
6 0.25 mg/kg
(i.v.)
0.25 mg/kg
(i.v.)
COC plasm concentration:
170.3±24.1 (ng/mL);
CE plasm concentration:
159.6±30.5 (ng/mL).
CE: smaller elimination rate and
longer t1/2.
(Perez-Reyes,
Jeffcoat, Myers,
Sihler, & Cook,
1994)
8 0.92 mg/kg
(i.n.)
0.48 mg/kg
(i.n) or 0.95
mg/kg (i.n)
- Similar euphoric and
cardiovascular effects for COC
and CE (HR, BP);
CE: smaller VD, slower
clearance, longer t1/2.
(McCance, Price,
Kosten, & Jatlow,
1995)
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Number of
subjects
studied
COC dose
(route of
administra
tion)
EtOH dose
(route of
administrati
on)
CE dose
(route of
administratio
n)
Mean peak values Mixture effects (compared
with COC and EtOH alone)
Reference
8 100 mg/kg
(i.n.)
0.8 g/kg
(oral)
COC plasm concentration:
330.5±111.7(ng/mL);
CE plasm concentration:
48.4±14.7(ng/mL);
EtOH plasm concentration:
1003.4±172.4 (ng/mL);
Higher HR and BP. (Farre et al., 1997)
8 4 doses of
1 mg/kg
every 30
min (i.n.)
1 g/kg after
the first COC
dose;
120 mg/kg at
60 min (oral)
COC plasm concentration:
893±114 (ng/mL);
CE plasm concentration:
114±18 (ng/mL);
EtOH plasm concentration
for first and second
administrations:
99±7 mg/dL;
118±10 mg/dL.
Increased cardiovascular effects,
including HR and BP, greater
euphoria and mental and
physical well-being (“feel good”);
(McCance-Katz,
Kosten, & Jatlow,
1998)
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1.5.2. Cocaine (COC) and heroin (HER) co-use
COC and opioids can be taken simultaneously or separately, in succession; either
by smoking, snorting, or i.v. injection. The simultaneous use of COC and opioids (e.g. HER
or MOR) is referred to as speedball (Rhodes, Briggs, Kimber, Jones, & Holloway, 2007). In
general, consumers of speedball are socially marginalized users, who smoke or inject COC
(Decorte, 2001; Gossop, Griffiths, Powis, & Strang, 1994; Leri, Bruneau, & Stewart, 2003).
Co-users that inject these drugs are more prone to risk of being exposed to transmitted
infections, such as Human immunodeficiency virus (HIV). They also present higher
incidence of personality disorders and worse treatment outcomes (DeMaria, Sterling, &
Weinstein, 2000; Downey, Helmus, & Schuster, 2000; Hudgins, McCusker, & Stoddard,
1995; King, Kidorf, Stoller, Carter, & Brooner, 2001). In addition, due to the short t1/2 of
injectable COC, these health risks are increased by the high frequency of injections (Leri et
al., 2003).
HER is more lipophilic than MOR and, consequently, more readily to cross BBB.
HER is deacetylated in body by hCE1, hCE2, and PChE, producing active metabolites, such
as 6-monoacetylmorphine (6-MAM), 3-monoacetylmorphine (3-MAM) and MOR. The 6-
MAM is metabolized into MOR, and is used as biomarker for HER consumption (Andersson,
Bjorkhem-Bergman, & Beck, 2015). As HER and COC share the same metabolic pathways
(hCE1, hCE2, PChE, and CYP3A4), interactions between these drugs are expected to
occur during consumption of speedball, affecting the final outcomes attributable to each
drug alone (Kamendulis, Brzezinski, Pindel, Bosron, & Dean, 1996).
Recently, chemical interactions between COC and HER (or its metabolites) have
been described. Garrido et al. (2007) investigated the electrochemical behaviour of mixtures
of COC and HER or MOR. The electrochemical study of COC–HER interaction is not
available because these drugs have similar potentials (probably because both drugs
present only one oxidation peak that represent the anodic oxidation of the tertiary amine
group). Results from COC–MOR combination suggest a marked interaction between the
drugs, as the oxidation peak of the phenolic group of MOR decreased with increasing
concentrations of COC. The authors suggested the formation of a complex or adduct of
COC with either MOR or HER, although they acknowledged that COC–HER interaction is
more difficult to occur due to the presence of the two terminal –O(C=O)CH3 groups in the
molecule of HER that hamper the COC molecule docking; the two aromatic rings of MOR
make the molecule more favourable to the interaction with COC because it does not
represent any significant steric hindrance. Since the 3-OH group of MOR is structurally
unavailable in the adduct form, and it is responsible for the interaction with the opioid
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receptors, this interaction probably changes the drug response at this level; note that HER
has to be previously deacetylated to promote brain effects.
In rat cortical neurons, sequential and simultaneous exposures to COC and HER
presented differences in the activated neurotoxic pathways. Sequential exposures led to a
major decrease in metabolic activity and increased cytochrome c release and,
consequently, apoptosis through caspase-3 activation; the simultaneous exposure
increased intracellular calcium levels, decreased mitochondrial membrane potential, and
decreased adenosine-5’-triphosphate (ATP) levels, which resulted in both necrotic and
apoptotic cell death (Cunha-Oliveira et al., 2010). These two drugs were more toxic when
combined, compared to separate administrations. The higher level of cell death that
occurred during simultaneous exposure could be related to the presence of COC–MOR
adducts.
The mechanisms of action of COC and opioids are different. As already mentioned,
the neuropharmacological effects of drugs of abuse are closely related with extracellular DA
levels in the nucleus accumbens. Both COC and HER increase DA levels in nucleus
accumbens, but through different mechanisms. HER induces indirect activation of the
dopaminergic system by the activation of mu receptors, reducing the inhibitory effect of
GABA that is responsible for inhibiting dopaminergic neurones in nucleus accumbens;
whereas COC increases DA activity by blocking the re-uptake of DA, as aforementioned.
Accordingly, it has been reported that speedball induces a synergistic increase of
DA in the nucleus accumbens, when compared with COC or HER alone (Pattison,
McIntosh, Sexton, Childers, & Hemby, 2014). In addition to the greater DA levels in nucleus
accumbens, a significant decrease in DAT density, as well as an increase in the DAT
binding affinity, was observed for speedball. Studies demonstrated that DAT apparent
affinity is high and similar for COC and speedball i.v. administrations, but significantly
different from results attained for HER (Pattison, McIntosh, Budygin, & Hemby, 2012).
Pattison et al. (2012) demonstrated that both chronic COC or speedball use increase affinity
of low-affinity DAT binding site. So, it is possible that the change on the DAT binding site
when COC is consumed alone or in combination might be attributed to COC, and not directly
related to speedball-induced DA elevations (Pattison et al., 2014).
Of note, these drugs present some opposite effects, which are explained by their
action at the noradrenergic system; HER reduces NA activity, while COC increases
extracellular NA by blocking its re-uptake at the nerve terminals (Leri et al., 2003;
Maldonado, 1997).
When HER and COC are co-used the effects in CNS can be annulated because
opioids depress the CNS, while COC stimulates it. On the other hand, their concomitant
use can lead to breathing difficulties, since both drugs induce respiratory depression,
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increasing the risk of overdose (EMCDDA, 2009). In addition, the simultaneous use of COC
can reduce intake of opioids and eliminate physical dependence, as users reveal that they
inject equal or higher doses of COC, but less HER, as self-medication to reduce
dependence on opioids.
Combination with COC can also affect other properties of opioids. COC use in
patients being treated with methadone produces lower blood levels of methadone because
COC increases methadone elimination. COC also increases the analgesic efficacy of MOR
in rats, mice, and monkeys (Gatch, Negus, Butelman, & Mello, 1995; Hunt, Lipton,
Goldsmith, & Strug, 1984; Misra, Pontani, & Vadlamani, 1987; Nott, 1968; Shimada, Tsuda,
& Yanagita, 1988; Sierra et al., 1992).
Ward et al. (2005) investigated the effects of HER on COC reinforcing effects, using
two different self-administration procedures in male rats. Subjects exposed to 1.5 mg
COC/kg/infusion presented an average breakpoint (defined as the number of infusions
obtained each day) of 17.3±0.67; supplementation with HER (1.5 to 48 µg/kg/infusion) did
not produce a significant change on response. Higher doses of COC (0.38 to 3.0
mg/kg/infusion) increased the number of breakpoints, but the addiction of HER (3.0 to 48
µg/kg/infusion) did not significantly changed the observed effects. In this procedure, results
on reinforcing effects obtained for all speedball combinations tested did not deviate from
those attained for COC alone. However, when rats were able to choose, they exclusively
opted for COC over HER, and for speedball combinations (e.g., 0.18 mg COC/kg/infusion
+ 50 µg HER/kg/infusion; 0.38 mg COC/kg/infusion + 50 µg HER/kg/infusion) over COC
alone (0.75 mg/kg/infusion) (Ward et al., 2005).
In a study performed in males with a recent history of drug abuse, two subjects
smoked three increasing doses of HER. The same subjects administered intravenously
three increasing doses of the drug, on distinct occasions. Saliva and blood were analysed
for the presence of HER and its metabolites (6-MAM and MOR); results are presented in
Tables 4 and 5 (Jenkins, Oyler, & Cone, 1995). Robust conclusions regarding the influence
of interindividual variability and the administration route on the drug bioavailability were
precluded by the absence of standardization of the administered doses among different
individuals and among the route of administration. Notwithstanding, from the observed
results, it is evident that saliva is a more valuable matrix for detecting smoked HER, while
blood must be considered for sampling, when the drug is administered intravenously. HER
was detectable in saliva for a longer period than in blood, after smoking the drug; the
detection periods in blood and saliva were similar for i.v. administration (Jenkins et al.,
1995).
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Table 4. Peak concentrations (ng/mL) of parent drug and its metabolites, quantified in saliva (S) and blood (B),
after heroin (HER) administration by smoking or intravenous (i.v.) injection in a male volunteer with a recent
history of drug abuse (subject A). The S/B ratio is also presented. 6-MAM: 6-Monoacetylmorphine. MOR:
Morphine. Adapted from Jenkins et al. (1995).
Dose
administered
HER 6-MAM MOR
Saliva Blood S/B Saliva Blood S/B Saliva Blood S/B
Sm
ok
in
g
2.6 mg 3,534 159.00 37.20 1,114 67.80 25.00 76.00 9.10 9.10
5.2 mg 20,580 51.00 784.30 3,577 21.10 333.60 142.00 4.60 29.40
10.5 mg 11,700 299.00 39.10 3,510 140.00 36.40 76.00 56.00 4.30
I.V
.
5 mg 22.00 42.00 0.91 18.00 32.90 0.71 0 12.70 0
10 mg 6.00 72.00 0.37 45.00 39.50 7.20 8.00 16.10 0.87
20 mg 20.00 401.00 0.44 141.00 312.00 5.51 15.00 57.00 1.18
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Table 5. Peak concentrations (ng/mL) of parent drug and its metabolites, quantified in saliva (S) and blood (B),
after heroin (HER) administration by smoking or intravenous (i.v.) injection in a male volunteer with a recent
history of drug abuse (subject B). The S/B ratio is also presented. 6-MAM: 6-Monoacetylmorphine. MOR:
Morphine. Adapted from Jenkins et al. (1995).
Dose
administered
HER 6-MAM MOR
Saliva Blood S/B Saliva Blood S/B Saliva Blood S/B
Sm
ok
in
g
3.5 mg 4,340 16.70 416.30 750.00 14.00 78.10 37.00 3.30 12.80
7.0 mg 11,420 52.50 217.50 1,370 14.90 114.10 6.00 29.70 0
10.5 mg 9,320 108.00 159.90 640.00 55.00 17.40 23.00 9.10 0
I.V
.
3 mg 9.00 64.50 0.14 18.00 28.60 1.04 4.00 8.40 0
6 mg 20.00 315.00 0.45 28.00 126.70 1.78 8.00 105.00 0.98
12 mg 30.00 141.00 1.90 77.00 151.00 5.26 15.00 44.00 1.82
In this study, seven subjects smoked a single dose of 40 mg of COC. Similarly, they
also were intravenously administered 44.8 mg of COC. COC and its metabolites (AEME,
BE, BZE, CE, EEE, EME, NBE, NCE, and NCOC) were then quantified in saliva and blood.
All subjects who smoked 40 mg of COC presented higher concentrations of COC in saliva,
compared to blood; the highest concentrations of COC were detected in saliva 2 min after
administration, and ranged from 15,85 to 504,88 ng/mL; these concentrations rapidly
declined. Also, the metabolites BZE, EME, NCOC, and AEME were detected, but in lower
levels. After the i.v. administration of 44.8 mg of COC, the drug peak concentrations in saliva
were lower than those achieved after smoking, ranging from 1.93 ng/mL to 428.00 ng/mL;
COC peak concentrations in plasma ranged from 122.00 to 442.00 ng/mL. In conclusion,
the saliva is a good biologic matrix for the two routes of COC administration.
Hair is a biological matrix that can be used for a retrospective identification of
substances that have short t1/2 in other biological matrix, such as blood and urine. In a case
report, hair was important to exclude the hypothesis of acetaminophen-codeine ingestion
and to ascertain that the baby was chronically exposed to COC and HER (Table 6) (Joya
et al., 2011).
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Table 6. Toxicological findings in the hair of a baby admitted to the emergency room and of his parents. COC:
Cocaine. BE: Benzoylecgonine. MOR: Morphine. 6-MAM: 6-Monoacetylmorphine. Retrieved from Joya et al.
(2011).
Specimens
Length of hair
(cm)
COC
(ng/mg)
BE
(ng/mg)
MOR
(ng/mg)
6-MAM
(ng/mg)
Codeine
(ng/mg)
Patient’s
hair
2 17.5 2.2 2.4 8.1 0.4
Father’s
hairs
3 11.8 1.7 6.4 8.0 1.8
Mother’s
hair
12 (total)
0-3 2.5 1.6 0.4 0.8 0.1
3-6 3.7 2.1 0.2 0.6 0.1
6-9 4.4 4.3 0.2 0.7 0.05
9-12 3.0 5.5 0.3 0.7 0.1
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1.5.3. Cocaine (COC) and ecstasy (MDMA) co-use
Ecstasy is the popular name of 3,4-methylenedioxymethamphetamine (MDMA) , an
illicit amphetamine-like substance associated with the rave culture, all-night dance parties
occurring during the weekend. Recreational users of MDMA have high incidence of
polydrug use, such as consumption of MDMA in combination with amphetamine,
methamphetamine or COC (Khorana, Pullagurla, Young, & Glennon, 2004; Williams,
Dratcu, Taylor, Roberts, & Oyefeso, 1998; Winstock, Griffiths, & Stewart, 2001). In 2009,
the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)  reported that
more than 50 % of young adults that were COC users also used ecstasy in Cyprus, Ireland,
and United Kingdom; while the co-consumption of the these substances rounded 31 % for
young COC users in Italy and Portugal(2009).
The co-abuse of MDMA with powdered COC is known as “bumping up”, while “cloud
nine” refers to the co-abuse with smoked free-base COC (Khorana et al., 2004). This
combination has the intent of intensifying the desired psychostimulant effects of the single
drugs (Khorana et al., 2004). Despite the number of studies evaluating the toxicity of MDMA
and COC alone, there is a lack of information regarding the effects of COC–MDMA co-
administration.
Pharmacodynamic interactions may be expected between COC and MDMA, since
both drugs share similar mechanisms of action. COC blocks the presynaptic reuptake of
DA, NA, and 5-HT, generating an increase in the extracellular levels of these
neurotransmitters; whereas MDMA binding to the presynaptic 5-HT transporter (SERT)
inhibits the reuptake of 5-HT, which in turn activates DA release by stimulating 5-HT
receptors (Muller, Carey, Huston, & De Souza Silva, 2007) and/or by reversing the
transporter direction (Crespi, Mennini, & Gobbi, 1997). Evidence suggests that 5-HT is more
strongly related to the psychotropic effects of MDMA, compared to COC (Itzhak & Ali, 2006).
However, the dopaminergic toxicity induced by MDMA can be affected by the co-abuse of
COC.
Panos and Baker (2010) demonstrated that the combination of COC (10 or 20
mg/kg) and MDMA (1.5 or 3.0 mg/kg) increased the extracellular DA levels and the
locomotion in rats. Importantly, in this work, the authors vindicated the occurrence of a
synergistic effect, as for the mixture administration the measured parameters increased to
a greater extent than the increase observed for the administration of either drug alone.
Although one must acknowledge this noticeable mixture effect, more caution should be
taken by the authors when assuming synergisms, as no expectations for the effects of the
combination were provided. Since it is in relation to the additivity calculations that mixture
outcomes are evaluated in terms of synergisms (effects greater than additive) or
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antagonisms (effects falling short of additivity), conclusions about the type of effect
observed are precluded in this study.
Diller et al. (2007) reported that in adult male rats co-administration of 5 mg/kg COC
and 5 mg/kg MDMA antagonized the rewarding effects of the single drugs, as demonstrated
by COC suppression of conditioned place preference (CPP) for MDMA. However, in the
same study, it was described that for higher doses of COC and MDMA, the respective drug
seeking was reversed. Some research has enlightened that the age of the animals can
influence the pre-treatment effect; accordingly, MDMA pre-treatment increased COC-
induced CPP in adolescent rats, while decreased it in adults. In this regard, exposure to
MDMA during adolescence can render the individuals more prone to polydrug abuse and,
therefore, more susceptible to the associated risks, than during adult age (Aberg, Wade,
Wall, & Izenwasser, 2007). In mice, exposure to MDMA during adolescence lead to long-
lasting neural adaptations to COC reward effects (Achat-Mendes, Anderson, & Itzhak,
2003). Evidence suggested that also differential social and environmental housing
conditions can change the response to MDMA in male adolescents rats and increase COC
reward (Starosciak, Zakharova, Stagg, Matos, & Izenwasser, 2012).
Additional evidence that MDMA can increase vulnerability to the development of
COC dependence was given by Morgan and collaborators (1997) who verified that the pre-
treatment of rats with MDMA increased 400% the extracellular levels of DA in nucleus
accumbens.
The individual pharmacokinetics of COC and MDMA can also be affected when the
drugs are associated, as they are both metabolized by CYP450; therefore, potential
toxicodynamic interactions could be expected.
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2. AIMS
Over the last 10 years, COC has become the second most used illicit drug in Europe
– COC snorting is now the most frequent recreational drug habit after smoking cannabis
(EMCDDA, 2012). In 2014, 3.4 million European adults (1% of this population group) have
used COC (EMCDDA, 2015). The consumption of this substance became a serious public
health concern due to its increasing abuse, but also to its unpredictable acute cardiac and
hepatic toxicity, detrimental effects on cognitive functioning, and well-known addictive
properties. Similarly to other illicit drugs, COC is all too often taken in recreational contexts
combined with other substances. This polydrug abuse pattern hampers toxicological
evaluation, as it challenges the establishment of a direct link between detrimental outcomes
and a particular drug. In addition, unique random reactions can result from the combination,
greatly worsening the associated health risks.
Although COC polydrug abuse is a very common practice, it received rather little
attention by the scientific community, when compared with the drug alone. Therefore, this
project aimed at increasing the understanding of the toxicological interactions between COC
and a few psychoactive agents that are commonly associated with the drug, i.e. HER/ MOR,
EtOH, and MDMA. More specifically, the purposes of this work were:
1. To assess whether the cardiotoxic and hepatotoxic effects of mixtures of COC and
frequently co-abused substances could be accurately predicted based on the
concentration-response data of the individual components, using the models of CA and IA.
2. To classify the mixtures as additive, synergistic or antagonistic by comparing
experimental observations with the additivity expectations according to both models.
3. To improve the understanding of the signalling mechanisms underlying the toxicity
observed for these mixtures.
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3. Materials and methods
3.1. Materials
All chemicals used in this study were of analytical grade. Dimethyl sulfoxide
(DMSO), ethylenediaminetetraacetic acid (EDTA), Folin–Ciocalteu reagent, perchloric acid
(HClO4), sodium hydroxide (NaOH), cupper (II) sulphate (CuSO4), sodium carbonate
(Na2CO3), potassium bicarbonate (KHCO3), magnesium sulphate (MgSO4), potassium
dihydrogen phosphate (KH2PO4), calcium dichloride (CaCl2), EtOH, and disodium
phosphate (Na2HPO4) were purchased from Merck (Darmstadt, Germany). Sodium
phosphate monobasic (NaHPO4) was purchased from Panreac (Barcelona, Spain),
potassium sodium tartrate tetrahydrate (KNaC4H4O6.4H2O) from Fluka (Buchs SG,
Switzerland) and sodium chloride (NaCl) was purchased from VWR (Leuven, Belgium).
Unless stated otherwise, all other chemicals were purchased from Sigma-Aldrich (Lisbon,
Portugal), including COC, HER, and MOR; and all the cell culture reagents were purchased
from Gibco (Alfagene, Lisbon, Portugal).
3.2. Animals
Male Wistar Han rats weighting between 200 and 250 g were purchased from
Charles-River Laboratories (Barcelona, Spain) and acclimated in polyethylene cages, for at
least 2 weeks prior to use, under controlled temperature (20±2 °C), humidity (40–60%) and
lighting (12 h light/dark cycle) conditions. The animals had ad libitum access to standard rat
chow and tap water. On the day of the experiments, the animals were anesthetized with
isoflurane prior to the surgical procedures for the isolation of hepatocytes, which were
carried out always between 10:00–11:00 a.m. The experiments included in this study were
approved by the local committee for the welfare of experimental animals and by the Ethic
Commission of the Faculty of Pharmacy of University of Porto, and were performed in
accordance with the national Law No. 1005/92, of 23rd October, Article 3, paragraph b, sub-
paragraph iii) by investigators accredited by the national authority Direcção Geral de
Alimentação e Veterinária (DGAV) for laboratory animal use.
3.3. Isolation and culture of hepatocytes
Isolation of hepatocytes was performed by collagenase perfusion, as previously
described by Valente et al. . Briefly, after perfusion with 600 µM ethylene glycol-bis(β-
aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA, a chelation agent that allows the
cleavage of the hepatic desmosomes), hepatic collagen was hydrolysed by ex situ perfusion
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with 100 U/mL Clostridium histolyticum collagenase type 1 solution, supplemented with 5.3
µM CaCl2. The hepatocytes were dissociated in Krebs–Henseleit buffer [0.42 M NaCl, 16.9
mM KCl, 4.2 mM MgSO4.7H2O, 9.1 mM CaCl2.2H2O, 4.2 mM KH2PO4, 25.5 mM NaHCO3,
pH 7.4] supplemented with 12.5 mM HEPES and 1% bovine serum albumin (BSA). The
obtained hepatocyte suspension was purified by low-speed 5 min-centrifugations at 250 x
g and incubated for 30 min at 4 °C, with 1% antibiotic solution (10,000 U/mL penicillin;
10,000 µg/mL streptomycin). The initial viability of isolated hepatocytes estimated by the
trypan blue exclusion test was always above 85%. A suspension of 5×105 viable cells/mL
was prepared in complete culture medium, plated at an appropriate cell density, and
incubated overnight at 37 °C in a humidified 5% CO2 – 95 % air atmosphere. The complete
cell culture medium consisted of William’s E medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 2 ng/mL insulin solution from bovine pancreas
(Sigma-Aldrich, Lisbon, Portugal), 5 nM dexamethasone (Sigma-Aldrich, Lisbon, Portugal),
1% antibiotic solution (10,000 U/mL penicillin; 10,000 µg/mL streptomycin), 10 μg/mL
gentamicin, and 0.25 µg/mL amphotericin B.
3.4. H9c2 cell culture
H9c2 cells were generously provided by Dr. Vilma Sardão from The Centre for
Neurosciences and Cellular Biology of University of Coimbra, Portugal. The cells were
cultured in 75 cm2 flasks Corning® (VWR, Lisbon, Portugal) with Dulbecco’s modified
Eagle’s medium – high glucose, supplemented with 10% FBS, 1% antibiotic solution
(10,000 U/mL penicillin; 10,000 µg/mL streptomycin) and 1% MEM non-essential amino
acids (NEAA). Cells were maintained at 37 °C in a humidified 5% CO2 – 95 % air
atmosphere and fed every 2–3 days. When the flasks reached 70–80% confluence, the cell
culture medium was removed and cells were washed with pre-warmed Hank’s balanced
salt solution (HBSS); then cultures were passaged by trypsinization (0.25% trypsin solution
with 1 mM EDTA) and were sub-cultured over a maximum of 10 passages.
3.5. Mixture testing
COC was combined with HER (Mix A; HER 2: COC 1), MOR (Mix B; MOR 2: COC
1), EtOH (Mix C; EtOH 9: COC 1), or MDMA (Mix D; MDMA 5: COC 1) at realistic mixture
ratios, i.e. at the same mixture ratio found in the blood of intoxicated abusers (Jenkins,
Levine, Titus, & Smialek, 1999) or in seized ecstasy pills (information retrieved from
http://www.ecstasydata.org/view.php?id=3554 accessed on July 5, 2016).
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3.6. Drug exposures
After seeding, primary rat hepatocytes and H9c2 cells were incubated overnight at
37 °C with 5% CO2 for cell adhesion. In the next day, cells were exposed to the drugs and
their mixtures in complete cell culture medium for 24 h. The 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) viability assay was performed both in primary and
immortalised cells to evaluate cytotoxicity elicited by treatments. Primary hepatocytes were
exposed to COC, EtOH, HER, MDMA, Mix A, Mix C, and Mix D; while H9c2 cells were
exposed to COC, EtOH, MOR, MDMA, Mix B, Mix C, and Mix D. All these treatments were
tested at a large range of concentrations, so that complete concentration–response
relationships could be recorded.
Besides the MTT viability assay, additional assays were performed in H9c2 to clarify
the underlying mechanisms of cardiototoxicity induced by COC, EtOH, MOR, MDMA, Mix
B, Mix C, and Mix D. These experiments were conducted by testing all treatments at the
respective concentrations producing 30% and 60% of the maximal effect in the viability
assay (EC30 and EC60, respectively) – these effect concentrations were estimated on the
basis of the concentration-response curves obtained for the corresponding treatments in
the MTT assay.
All stock solutions of the testing drugs and their mixtures were made in HBSS, stored
at -20 °C, and freshly diluted on the day of the experiment. By employing the fixed mixture
ratio design (Altenburger et al., 2000), a range of concentrations of each mixture was
subsequently prepared for testing, maintaining the ratio between each constituent
unchanged. Positive and negative controls (complete cell culture medium) were performed
parallel to drug incubations.
3.7. Determination of cell viability
The MTT assay assesses cell viability indirectly through the measurement of activity
of enzymes that reduce the yellow soluble MTT to purple insoluble formazan salts. As MTT
can only be reduced when mitochondrial reductases are active, the conversion is used as
a measure of the organelle viability and, therefore, of cell viability. The purple formazans
are dissolved by DMSO, and the absorbance of the coloured solution quantified at 550 nm.
For the viability assay, H9c2 cells and primary rat hepatocytes were seeded at a
density of ~2×104 cells/cm2 and ~1.5×105 cells/cm2, respectively, onto the central 60 wells
of the 96-well plates (BD Falcon, Enzifarma, Lisbon, Portugal). After 24h-incubations with
the testing drugs, the cell culture medium was aspirated from the plate and 100 μL of 1
mg/mL MTT (Sigma-Aldrich, Lisbon, Portugal) solution was added to each well. The cells
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were further incubated at 37°C, for 4h (H9c2 cells) or 1h (rat hepatocytes). Then, the MTT
solution was aspirated and the formed crystals were dissolved with 100 μL of DMSO. The
plate was shaken for 15 min, protected from light. The absorbance was measured at 550
nm, directly in the plate, using a multi-well plate reader BioTek SynergyTM HT (BioTek
Instruments, Inc.).
All steps of the procedure were executed under the light protection because MTT is
photosensitive. The results were normalised with negative and positive (1% Triton X-100)
controls and results were graphically presented as percentage of cell death versus
concentration (mM).
3.8. Prediction of mixture effects
The expected mixture effects were calculated using two pharmacological models of
additivity that are widely employed in the mixture toxicity field, concentration addition (CA)
and independent action (IA).
The foundations of CA model are that mixture constituents act by a similar mode of
action, which means that any component contributes to the global effect in proportion to its
concentration, even when present at concentrations that do not produce effect. Presuming
that the effect of a mixture with n components is concentration additive, the mixture effect
is calculated by = [∑ / ] , where ECmix is the mixture concentration eliciting
an effect of defined magnitude, pi is the fraction of each individual compound relative to the
total mixture concentration that is required to produce effect i, and ECi is the concentration
of each individual compound that can produce effect i.
It is preconized that the IA model is better applied to mixtures of drugs with different
mechanisms of action or interacting at differing sites. Thus, IA assumes that mixture
components present at zero effect concentrations will not contribute to the overall effect
because the fractional response of a single component is supposed to be independent of
those induced by other components. The mixture effect might be estimated by =[1 − ∏[1 − ( )/ ]], where Emax is the maximal measured effect, and Fi(ci)
the mean effect predicted by the regression model for each individual drug.
3.9. Samples preparation for determination of adenosine-5’-triphosphate
(ATP) and reduced (GSH) and oxidized glutathione (GSSG)
H9c2 cells were seeded onto 6-well plates at a density of ~2×104 cells/cm2, and
incubated overnight. Then, cells were incubated with the testing drugs and, after 24h, the
exposure medium was collected into a centrifuge tube. The cells were washed twice with 1
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mL of HBSS with Ca and Mg, and the washing buffer was also collected into the centrifuge
tube containing the exposure medium. After centrifugation for 10 min at 16,000 x g in a
refrigerated centrifuge (4 °C), the supernatant was rejected, and the pellet kept on ice. The
cells were added of 300 μL 5% HClO4 and the plate was kept on ice, for 20 min. After
scrapping, cell suspension was transferred into the centrifuge tube placed on ice; the cell
pellet was resuspended and sample centrifuged at 4 °C for 10 min at 16,000 x g. The
supernatant was collected into a clear microcentrifuge tube and kept at -80 °C until further
determination of ATP, reduced glutathione (GSH) and oxidized glutathione (GSSG). The
pellet was resuspended in 0.3 M NaOH and used for protein quantification.
3.10. Determination of reduced (GSH) and oxidized glutathione (GSSG)
The quantification of total GSH (GSHt) in H9c2 cells was performed through the 5,5′-
dithiobis(2-nitrobenzoic acid) (DTNB)-GSSG reductase-recycling assay. Briefly, after
neutralizing the supernatants of samples, blank and standards with 0.76 M KHCO3 (until
there was no formation of CO2 following vortex mixing), the microcentrifuge tubes were
centrifuged for 10 min at 16,000 x g (4 °C). Then, 100 μL of each supernatant were added
to a 96-well plate, followed by 65 μL of a freshly prepared reagent solution containing 0.24
mM NADPH and 0.7 mM DTNB, prepared in a phosphate buffer (71.5 mM NaHPO4, 71.5
mM Na2HPO4, and 0.63 mM EDTA, pH 7.0). Samples were incubated for 15 min at 30 °C.
Then, 40 µL of 10 U/mL glutathione reductase (GR, Sigma-Aldrich) solution (freshly
prepared in phosphate buffer) were added to each well. The consequent formation of 5-
thio-2-nitrobenzoic acid (TNB) was followed for 3 min, every 10 sec, at 405 nm, using a
multi-well plate reader (Power Wave XTM, BioTek Instruments, Inc.).
To determine intracellular GSSG, 10 μL of 2-vinylpyridine (Sigma-Aldrich) were
added to 200 μL of neutralised supernatants (samples, blank, and standards) and mixed for
1h, on ice. As 2-vinylpyridine blocks GSH, GSSG will be determined as described for GSHt.
The amount of GSH was calculated by subtracting GSSG from the GSHt, i.e. GSH=GSHt–
(2xGSSG).
The GSSG and GSH standard solutions were prepared in 5% HClO4; the
concentrations ranged between 0.10 and 13 µM for GSSG, and between 0.33 and 13 µM
for GSH. Results were compared with the respective standard curve, normalised to the
amount of protein, and presented as nmol per mg of protein.
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3.11. Determination of adenosine-5’-triphosphate (ATP)
The intracellular level of ATP was determined through the luciferin–luciferase
bioluminescence assay that measures the light formed in the oxidation of luciferin, catalysed
by luciferase in the presence of ATP. The amount of ATP is directly proportional to the
emitted light intensity (maximum at ~560 nm, pH 7.8).
After neutralizing the supernatants of samples, blank, and standards with 0.76 M
KHCO3 (until there is no formation of CO2 following vortex mixing), the microcentrifuge tubes
were centrifuged for 10 min at 16,000 x g (4 °C). After that, 75 μL of each supernatant (4
°C) was transferred into a 96-well plate and added of 75 μL of luciferin-luciferase reagent
(4 °C, protected from light), immediately before the luminescence readings. Results were
compared with the standard curve, normalised to the amount of protein, and presented as
nmol ATP per mg of protein. The ATP (Sigma-Aldrich) standard solutions were prepared in
5% HClO4; the concentrations ranged between 1.25 and 20 µM.
3.12. Determination of protein
The protein content in the samples was measured through the method of Lowry
(1951). Accordingly, 50 μL of each sample, standard, or blank were transferred into a 96-
well plate, in triplicate, and added of 100 μL reagent A (14.7 mL of 2% Na2CO3, 0.15 mL of
2% KNaC4H4O6.4H2O, and 0.15 mL of 1% CuSO4.5H2O, extemporaneously prepared). The
plate was incubated in the dark for 10 min, at room temperature, followed by the addition of
100 μL of reagent B (Folin and Ciocalteu’s phenol reagent, diluted 15x in purified water).
The plate was incubated for 20 min, under light protection, at room temperature, and the
absorbance was measured at 750 nm in a 96-well microplate reader (Power Wave XTM,
BioTek Instruments, Inc.). Protein standards were prepared with BSA in 0.3 M NaOH
(concentrations between 31.25 μg/mL and 500 μg/mL).
3.13. Measurement of reactive species
Measurement of intracellular ROS and RNS was made by a fluorescent assay that
uses 2’,7’-dichlorofluorescin diacetate (DCFH-DA), a non-fluorescent lipophilic compound
that passes through the cell membrane, being deacetylated to 2’,7’-dichlorofluorescin
(DCFH) by intracellular esterases. DCFH is a sensitive probe that reacts with intracellular
ROS and RNS to generate a green fluorescent polar compound, 2’,7’-dichlorofluorescein
(DCF), which is trapped within the cells.
In our experiments, H9c2 cells were seeding onto 96-well plates at a density of
~2×104 cells/cm2. Before drug exposures, the cell culture medium was gently aspirated,
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cells were washed twice with HBSS and incubated with 100 μL of 10 μM DCFH-DA (Sigma-
Aldrich) for 30 min, at 37 °C. At the end of the incubation period, cells were washed twice
with HBSS and added of 100 μL of testing solutions. Following incubation with the
treatments at 37 °C for 24h, fluorescence was read in a multi-well plate reader (BioTek
SynergyTM HT) set to 485 nm excitation and 530 nm emission. As DCFH-DA is
photosensitive, all steps of the procedure were executed under light protection.
3.14. Evaluation of mitochondrial integrity (Δѱm)
Mitochondrial integrity was assessed by measuring the tetramethylrhodamine ethyl
ester perchlorate (TMRE) inclusion. This cell permeable fluorescent dye specifically stains
live mitochondria, accumulating in proportion to the mitochondrial membrane potential
(Δѱm).
The H9c2 cells were seeding onto 96-well plates at a density of ~2×104 cells/cm2
and incubated at 37°C overnight. On the day of the experiment, cells were exposed to the
drugs for 24h. Then, the exposure medium was gently removed, the cells were washed
twice with HBSS, added of 100 μL of 2 μM TMRE (Sigma-Aldrich), and incubated for 30
minutes at 37 oC. Cells were washed twice and added of 100 μL of HBSS. The fluorescence
was read in a multi-well plate reader (BioTek SynergyTM HT) set at 544 nm excitation and
590 nm emission.
3.15. Determination of cell membrane integrity
Cytoplasmic membrane integrity was evaluated through the lactate dehydrogenase
(LDH) leakage assay. As LDH is a cytoplasmic oxidoreductase, its presence in the
extracellular medium is indicative of alterations in membrane permeability and consequently
in cell integrity. The enzyme catalyses the reversible conversion of pyruvate to lactate, in
the presence of nicotinamide adenine dinucleotide (NADH), which by turn is oxidized to
NAD+.
H9c2 cells were seeding into a 96-well plate at a density of ~2×104 cells/cm2. At the
end of the incubation period, 50 μL of supernatant was transferred into a 96-well plate and
added of 200 μL of freshly prepared 0.15 mg/mL β-nicotinamide adenine dinucleotide (β-
NADH) solution. Immediately before the absorbance reading, 25 μL of 2.5 mg/mL sodium
pyruvate solution were added to start the reaction. Both β-NADH and sodium pyruvate were
prepared in potassium phosphate buffer (KH2PO4, pH 7.4). The kinetic of the oxidation of
NADH to NAD+ was followed by reading the absorbance at 340 nm, every 16 seconds, for
3 minutes, using an automatic plate reader Power Wave XTM (BioTek Instruments, Inc.).
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4. Results
4.1. Mixture effects of cocaine (COC) and other drugs frequently co-abused
For the accurate calculation of the effects of a given mixture, besides knowledge on
its exact composition, information on the effects of all single drugs is required. Therefore,
to ensure great precision of our predictions, the utilisation of a highly reproducible assay is
demanded. Moreover, this has to be able to produce large amounts of highly reliable data
for every component of the mixture, in a relatively short period of time. Accordingly, the MTT
reduction assay was selected to evaluate the effects of different mixtures of COC on cell
viability, in two different cell models, i.e. hepatocytes and cardiomyocytes. The data attained
was then used for the assessment of the type of interaction (synergism, additivity, or
antagonism) that occurred between COC and MOR (Mix B), COC and EtOH (Mix C), and
COC and MDMA (Mix D), in H9c2 cells; and between COC and HER (Mix A), COC and
EtOH (Mix C), and COC and MDMA (Mix D), in primary rat hepatocytes.
4.1.1. Hepatotoxicity elicited by cocaine (COC) combined with heroin
(HER), ethanol (EtOH), or ecstasy (MDMA)
The assessment of combination effects in terms of synergisms, antagonisms, or
additivity critically depends on the determination of the expected effects of a given mixture,
and on the subsequent comparison of these calculations with the mixture effects
experimentally attained. As already mentioned, in order to produce the data required for
calculating predictions of mixture effects, extensive concentration–response analyses of all
individual mixture components had to be carried out. Therefore, we first analysed the
mortality elicited by COC, HER, EtOH, and MDMA alone, after exposures of primary
hepatocytes for 24 h.
As observed in Figure 5 in primary hepatocytes, all single drugs produced complete
mortality profiles, i.e. concentration-dependent responses ranging from 0% to 100% cell
death. The presented data were produced in four different occasions, using independently
prepared serial dilutions of all chemicals; there was always good agreement between
experiments. Regarding the cytotoxic potency, EtOH (EC50 263.26 mM) was less toxic than
COC (EC50 1.07 mM), MDMA (EC50 0.56 mM), and HER (EC50 0.26 mM). In what concerns
the slope, MDMA was the drug presenting the steepest curve. A summary of the best-fit
regression model parameters (including location and slope) and the concentrations that
individually produce 50% of the maximal effect (EC50) for each drug are presented in Table
7.
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Figure 5. Cytotoxicity elicited by cocaine (COC), heroin (HER), ethanol (EtOH), and ecstasy (MDMA) in primary
rat hepatocytes, after 24 h-exposure, at 37 °C. Data assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay are from four independent experiments (in triplicates) and are
presented as percentage of cell death (relative to the negative controls). The solid lines are the best estimate of
mean responses given by the dosimetric Logit model, and the dotted lines are the respective upper and lower
limits of the 95% confidence interval. The dashed grey lines represent 50% and 100% effect.
After thoroughly characterize the concentration–effect relationships of individual
drugs in terms of shape, slope, and maximal effects (Table 7), the CA and IA models were
applied to quantitatively fit the expected responses of three different mixtures. As observed
in Figure 6, in primary rat hepatocytes, the models CA and IA predicted roughly coincident
toxicity for both Mix A (EC50 0.37 mM and 0.37 mM, respectively), Mix C (EC50 9.02 mM and
9.03 mM, respectively), and Mix D (EC50 0.61 mM and 0.66 mM, respectively) (Table 8).
Effects experimentally obtained for Mix A (EC50 0.53±0.07 mM) were shifted to the
right, compared to predictions; for Mix C, were shifted to the left (EC50 5.60±0.30 mM); while
for Mix D, the effects calculated by CA were comprised in the 95% confidence belt of the
observed effects (EC50 0.55±0.10 mM). Consequently, the toxicity observed for Mix C was
higher than the calculated, indicating the occurrence of synergism between EtOH and COC;
the opposite occurred for Mix A, i.e. antagonism between COC and HER; while for Mix D,
predicted and observed toxicities were coincident suggesting that effects of COC and
MDMA are additive.
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Figure 6. Mortality elicited by the mixtures of cocaine 1: heroin 2 (Mix A), cocaine 1: ethanol 9 (Mix C), and
cocaine 1: MDMA 5 (Mix D), in primary rat hepatocytes, as assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay, after 24h of exposure, at 37 °C. Purple and red lines: mixture effects
predicted by independent action (IA) and concentration addition (CA), respectively. Black lines: experimental
mixture effects. Data are presented as percentage of cell death relative to the negative controls and are from a
minimum of four independent experiments, performed in triplicate. Curves were fitted to the dosimetric Logit
model (Table 7). The dotted lines are the upper and lower limits of the 95% confidence interval of the best
estimate of mean responses. The dashed grey lines represent 50% and 100% effect.
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4.1.2. Cardiotoxicity elicited by cocaine (COC) combined with morphine
(MOR), ethanol (EtOH), or ecstasy (MDMA)
Similar to results obtained for primary hepatocytes, all single drugs, i.e. COC, MOR,
EtOH, and MDMA, yielded reproducible concentration-dependent toxicity, when tested in
H9c2 cells. The cytotoxicity curves for each of the testing drugs, including the upper and
lower 95% CI, are displayed in Figure 7. Also, all drugs produced complete curves of
percentage of cell death versus drug concentration. Differences were observed essentially
in the EC50 values and in the slopes. Accordingly, EtOH with an EC50 of 305.26 mM was the
least toxic drug, followed by MOR (EC50 6.93 mM) and COC (EC50 2.60 mM). Contrarily,
MDMA was the most cardiotoxic drug (EC50 1.07 mM). These differences between EC50
values of the testing drugs were deemed statistically significant, as there was no overlap
between the corresponding 95% CI of the concentration–response curves (Figure 8).
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Figure 7. Cytotoxicity elicited by cocaine (COC), morphine (MOR), ethanol (EtOH), and ecstasy (MDMA), in
H9c2 cells, after 24h-exposure, at 37 °C. Data assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay are from four independent experiments (in triplicates) and are
presented as percentage of cell death (relative to the negative controls). The solid lines are the best estimate of
mean responses given by the dosimetric Logit model, and the dotted lines are the respective upper and lower
limits of the 95% confidence interval. The dashed grey lines represent 50% and 100% effect.
Using the data attained for COC, MOR EtOH, and MDMA in H9c2 cells, mixture
toxicity was predicted by CA and IA for Mix B (EC50 4.18 mM and 5.01 mM, respectively),
Mix C (EC50 21.75 mM and 22.95 mM, respectively), and for Mix D (EC50 1.19 mM and 1.28
mM, respectively) (Figure 8 and Table 8). Again, calculations from both models were
congruent, but CA revealed to be slightly more conservative (as EC50 values were
marginally smaller than those achieved for IA).
Experimental mixture testing at the conditions used for the individual drugs
demonstrated that, in H9c2 cells, the predicted toxicity was lower than the effects
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experimentally attained for mix B (EC50 1.90±0.23 mM) and mix D (EC50 0.41±0.20 mM)
(synergism) and roughly similar for mix C (EC50 19.18±3.36 mM) (additivity).
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Figure 8. Mortality elicited by the mixtures of cocaine 1: morphine 4 (Mix B), cocaine 1: ethanol 9 (Mix C), and
cocaine 1: MDMA 5 (Mix D), in H9c2, as assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay, after 24h of exposure, at 37 °C. Purple and red lines: mixture effects predicted by
independent action (IA) and concentration addition (CA), respectively. Black lines: experimental mixture effects.
Data are presented as percentage of cell death relative to the negative controls and are from a minimum of four
independent experiments, performed in triplicate. Curves were fitted to the dosimetric Logit model (Table 7).
The dotted lines are the upper and lower limits of the 95% confidence interval of the best estimate of mean
responses. The dashed grey lines represent 50% and 100% effect.
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Table 7. Parameters derived from the nonlinear fits of the single drugs. Concentration–mortality data from the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, obtained after 24h-incubations at 37
oC, were fitted to the asymmetric Logit function. These parameters were used to compute the mixture effects,
shown in Figures. 6 and 8. Mix A – mixture of cocaine (COC) and heroin (HER) at 1:2. Mix B – mixture of COC
and morphine (MOR) at 1:2. Mix C – mixture of COC and ethanol (EtOH) at 1:9. Mix D – mixture of COC and
ecstasy (MDMA) at 1:5
Estimated parameters for the regression model
EC50
Fraction in mixture
Θ1A Θ2B ΘMAXC Mix A Mix B Mix C Mix D
Primary hepatocytes
COC -0.31 3.24 112.20 1.07 0.38 - 0.11 0.17
HER 1.20 2.21 105.20 0.26 0.62 - - -
EtOH -5.56 2.12 127.00 263.26 - - 0.89 -
MDMA -6.67 8.84 102.00 0.56 - - - 0.83
Mix A 1.53 5.25 97.27 0.52 1.00 - - -
Mix C -1.99 1.47 172.1 5.60 - - 1.00 -
Mix D -18.90 25.49 101.10 5.52 - - - 1.00
H9c2 cells
COC -2.24 4.80 113.90 2.60 - 0.38 0.11 0.17
MOR -3.13 3.59 105.90 6.93 - 0.62 - -
EtOH -9.37 3.72 106.10 305.26 - - 0.89 -
MDMA -0.25 4.33 106.3 1.07 - - - 0.83
Mix B -1.17 3.93 103.80 1.91 - 1.00 - -
Mix C -8.78 6.81 102.30 19.18 - - 1.00 -
Mix D 1.08 2.5 103.00 0.41 - - - 1.00
a Location parameter of the Logit function.
b Slope parameter.
c Maximal effect, expressed as corrected % cell death.
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Table 8. Observed and predicted EC50 values for the tested combinations, i.e. mixture A (cocaine 1: heroin 2),
mixture B (cocaine 1: morphine 4), mixture C (cocaine 1: ethanol 9), and mixture D (cocaine 1: ecstasy 5) in the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, after 24h-incubations at 37 °C.
4.2. Mechanisms underlying the observed joint effects
In order to obtain an in-depth understanding of the pathways underlying the
observed toxicological effects, the three mixtures tested in H9c2 were further investigated.
Accordingly, alterations on a set of parameters related to mechanisms of oxidative and
mitochondrial stress were evaluated, specifically the intracellular contents of GSH, GSSG,
ATP, and ROS/RNS, and alterations on the mitochondrial membrane potential. Two
concentrations, corresponding to the respective EC30 and EC60, of each drug and their
mixtures were tested; these concentrations were estimated from the Logit regression model
of each data set obtained in the MTT assay (Table 9).
Table 9. Concentrations (mM) used for evaluating the mechanisms underlying cardiotoxicity of cocaine (COC),
morphine (MOR), ethanol (EtOH), and ecstasy (MDMA) when H9c2 were exposed to the drugs alone or in
combination (i.e. Mix B, Mix C, and Mix D), for 24 h at 37 °C. These concentrations correspond to the respective
EC30 and EC60, as obtained in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
Mix B: mixture of COC 1: MOR 2. Mix C: mixture of COC 1: EtOH 9. Mix D: mixture of COC 1: ecstasy (MDMA)
5.
Cell model Mixture
EC50 (mM) Combinationeffect
Predicted
by CA
Predicted
by IA Observed
Primary rat
hepatocytes
A 0.366 0.369 0.525±0.074 Antagonism
C 9.019 9.034 5.601±0.302 Synergism
D 0.606 0.660 0.552±0.102 Additivity
H9c2
cardiomyocytes
B 4.180 5.005 1.903±0.229 Synergism
C 21.753 22.946 19.183±3.360 Additivity
D 1.186 1.277 0.410±0.195 Synergism
EC30 EC60
COC 1.788 3.085
MOR 4.105 8.841
EtOH 184.338 385.781
MDMA 0.694 1.308
MIX B 1.172 2.388
MIX C 14.465 21.921
MIX D 0.215 0.557
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By neutralising intracellular reactive species, GSH is capable of preventing damage
to vital cellular components, such as proteins, lipids, and DNA; therefore, changes in the
intracellular contents of GSH and GSSG are important indicators of redox disturbance. Our
data from quantification of intracellular amounts of GSH and GSSG demonstrate that all
treatments disturbed thiol homeostasis, in H9c2 cells after 24 h-exposure, particularly, at
the highest concentration tested (EC60) (p<0.01, ANOVA/Holm-Sidak’s). The exception was
EtOH; although a decrease in tGSH was observed for both concentrations, it did not reach
statistical importance (p>0.05, ANOVA/Holm-Sidak’s). These changes on the intracellular
tGSH levels were strictly correlated with alterations on GSH contents (Figure 9). Also,
important modifications on intracellular GSSG were observed; these were more pronounced
for COC, when tested at the EC60 (p<0.05, ANOVA/Holm-Sidak’s). Moreover, this result was
significantly different from that produced by mixtures B and C, at the same concentration
(p<0.05, ANOVA/Holm-Sidak’s). Also MOR at EC60 and COC at EC30 yield tGSH results
that deviated from those obtained for Mix B and Mix C, respectively, tested at the same
concentrations (p<0.05, ANOVA/Holm-Sidak’s).
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Figure 9. Effect elicited by cocaine, morphine, ethanol, and mixtures B and C in the total glutathione (tGSH),
reduced glutathione (GSH), and glutathione disulfide (GSSG), in H9c2 cells, after 24 h-exposure at 37 oC. EC30
and EC60 are the concentrations producing 30% and 60% of effect, respectively, in the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability assay. Mixture B: mixture of COC 1: MOR 2. Mixture C:
mixture of COC 1: EtOH 9. Results normalized to the protein content represent the mean ± SEM. Statistical
comparisons were made by one-way ANOVA followed by Holm-Sidak’s multiple comparison post hoc test.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, compared to controls. #p<0.05, compared to mixture tested at the
same concentration.
Thiol antioxidant stores protect cells against oxidative injury, but the disruption of
glutathione homeostasis will render the cells vulnerable to the stress induced by free
PART IV: RESULTS
47
radicals. Accordingly, the results obtained in the DCFH-DA assay confirmed that all
treatments stimulated the production of ROS/RNS after 24 h-exposures, in H9c2 (Figure
10); these results were significant at the highest concentration tested (p<0.0001,
ANOVA/Holm-Sidak’s). Remarkably, Mix D, MDMA, and EtOH also induced significant
production of prooxidant species at the lowest concentration (EC30; p<0.05, vs. control;
ANOVA/Holm-Sidak’s). Similarly to results of GSH assay, COC and Mix C were significantly
different, when tested at the respective EC60 (p<0.05, ANOVA/Holm-Sidak’s).
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Figure 10. Reactive species of oxygen (ROS) and nitrogen (RNS) formed in H9c2, after exposure at cocaine,
morphine, ethanol, and mixtures B and C, for 24 h at 37°C. EC30 and EC60 are the concentrations producing
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30% and 60% of effect, respectively, in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
viability assay. Mixture B: mixture of COC 1: MOR 2. Mixture C: mixture of COC 1: EtOH 9. Mixture D: mixture
of COC 1: ecstasy (MDMA) 5. Results represent the mean ± SEM of the fluorescence emitted when 2’,7’-
dichlorodihydrofluorescein (DCFH) reacts with reactive species, and were normalized to the controls. Statistical
comparisons were made by one-way ANOVA followed by Holm-Sidak’s multiple comparison post hoc test.
*p<0.05, ****p<0.0001, compared to controls. #p<0.05, compared to mixture tested at the same concentration.
Mitochondria is a major site for ROS/RNS production and a strong positive
correlation between ΔΨm and ROS production has been recurrently demonstrated, as
mitochondria produce more ROS at high membrane potential (Turrens, 2003). In
accordance, our data indicates that all treatments induced a significant increase of ΔΨm
(p<0.01, ANOVA/Holm-Sidak’s), measured through TMRE incorporation in mitochondria of
H9c2 cells (Figure 11). MORPH tested at EC30 was the only treatment that deviated from
mixture results (p<0.05 vs. EC30 Mix B, ANOVA/Holm-Sidak’s).
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Figure 11. Effect elicited by cocaine, morphine, ethanol, and mixtures B and C on the amount of
tetramethylrhodamine ethyl ester perchlorate (TMRE) incorporated within the mitochondria, as a measure of
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mitochondrial membrane potential, in H9c2 cells, after 24 h-exposure. EC30 and EC60 are the concentrations
producing 30% and 60% of effect, respectively, in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) viability assay. Mixture B: mixture of COC 1: MOR 2. Mixture C: mixture of COC 1: EtOH 9.
Mixture D: mixture of COC 1: ecstasy (MDMA) 5. Results were normalized to the controls and presented as
mean ± SEM. Statistical comparisons were made by one-way ANOVA followed by Holm-Sidak’s multiple
comparison post hoc test. **p<0.01, ***p<0.001, ****p<0.0001 compared to controls. #p<0.05, compared to
mixture tested at the same concentration.
Mitochondrial membrane potential is critical for preserving the functional integrity of
the respiratory chain and, therefore, of ATP generation. An increase in the ΔΨm has been
related to inhibition or dysfunction of ATP synthase (Geromel et al., 2001; Wojtczak et al.,
1999), with parallel increase of ROS production. In line with these observations, all
treatments induced a significant decrease of ATP, after 24 h-exposures, in H9c2 cells, as
shown in Figure 12. The exception was EtOH (EC30 and EC60) and Mix C (EC30).
Results on the energetic disturbance were significantly different for COC at EC30
(p<0.001, ANOVA/Holm-Sidak’s) and for EtOH at EC60 (p<0.05, ANOVA/Holm-Sidak’s),
when compared with results for Mix C, at the same concentrations.
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Figure 12. Effect elicited by cocaine, morphine, ethanol, and mixtures B and C in intracellular ATP, in H9c2 cells,
after 24 h-exposure. EC30 and EC60 are the concentrations producing 30% and 60% of effect, respectively, in
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability assay. Mixture B: mixture of
COC 1: MOR 2. Mixture C: mixture of COC 1: EtOH 9. Results normalized to the protein content represent the
mean ± SEM. Statistical comparisons were made by one-way ANOVA followed by Holm-Sidak’s multiple
comparison post hoc test. *p<0.05, **p<0.01, ***p< 0.001, ****p<0.0001 compared to controls. #p<0.05,
###p<0.001, compared to mixture tested at the same concentration.
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The inability of mitochondria to adequately supply cell with ATP, results in energy
deprivation to the cell and potentially necrotic/apoptotic cell death. Microscopic observation
of H9c2 cells exposed to our treatments, demonstrated alterations on cell morphology.
Compared to controls, these alterations were highly pronounced when cells were exposed
to the greatest concentration (EC60; Figure 13).
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Figure 13. Morphology of H9c2 cells by light microscopy after exposure to cocaine (COC), morphine (MOR),
ethanol (EtOH), ecstasy (MDMA), and mixtures B, C, and D, for 24 h at 37°C, at the respective EC60, i.e. the
concentration producing 60% of maximal effect in the MTT viability assay. Mix B: mixture of COC 1: MOR 2.
Mix C: mixture of COC 1: EtOH 9. Mix D: mixture of COC 1: ecstasy (MDMA) 5. Original magnification ×40.
Control COC
MOR Mix B
ETOH Mix C
MDMA Mix D
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In an effort to elucidate if these morphological alterations were accompanied by
disruption of cytoplasmic membrane integrity, we attempted to perform the evaluation of
intracellular LDH leakage. Unfortunately, by the time of the delivery of this dissertation, the
conditions of the assay were not yet optimised for our cellular model.
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5. Discussion
In the recreational scene, COC is taken along with other licit and illicit drugs of
abuse; among them, some of the most frequently associated with the drug are EtOH, HER
or its metabolite MOR, and MDMA. Of concern, polydrug abuse is one of the most relevant
bewildering factors in establishing the toxicological potential of drugs, as pharmacokinetic
and pharmacodynamic interactions may occur (Chan & Anderson, 2014; Collin et al., 2014;
Cunha-Oliveira et al., 2010; da Silva, Silva, Carvalho, & Carmo, 2014; Farre et al., 1997;
Kamendulis et al., 1996; Pontes et al., 2010) and are of serious consequence for the
development of unexpected intoxications, which ultimately can be lethal (EMCDDA, 2009;
Gossop et al., 2006; Grant & Harford, 1990; Kelly & Parsons, 2008; Leri et al., 2003).
We anticipated that potential interactions between COC and these co-consumed
substances could occur, since these drugs present overlapping mechanistic, metabolic and
detoxifying pathways (Antolino-Lobo et al., 2011; Chan & Anderson, 2014; He, Brockmoller,
Schmidt, Roots, & Kirchheiner, 2008; Pontes et al., 2010; Zhan, Hou, Zhan, & Zheng, 2014).
Therefore, we became very interested in evaluating whether COC in combination with
EtOH, HER, MOR, or MDMA would be able to yield toxicological effects, distinct from those
observed for the single drugs. With this intent, for the toxicological assessment we selected
two different in vitro models representative of important targets of COC toxicity, i.e. liver and
heart.
The liver is responsible for the biotransformation and removal of xenobiotics, which
implicates their accumulation in the organ prior to metabolic (de)toxification. Accordingly,
the principal COC metabolic pathways occur in this organ, among others, mediated by P450
enzymes such as CYP1A, CYP2A, CYP2B, and CYP3A (Yao, Shi, Wang, Gosnell, & Chen,
2013). In addition, the bioactivation of the drug has been pointed out as one of the main
causes of its hepatotoxic effects (Boelsterli & Goldlin, 1991; Ndikum-Moffor et al., 1998;
Pellinen et al., 1994; Thompson, Shuster, & Shaw, 1979).
Heart is further exposed to the formed metabolites through distribution via blood
stream, but the organ also contains enzymes whose metabolic activity adds to cardiac
toxicity. In accordance, COC is frequently associated with reports of cardiac damage
(Bauman et al., 1994; Fan et al., 2009; Fineschi et al., 2001; Graziani et al., 2016). Evidence
indicates that the drug blocks the reuptake of catecholamines, increasing the release of NA
from the adrenergic nerve terminals; the activation of sympathomimetic pathways results in
augmentation of ventricular contractility, increased blood pressure, heart rate, and
myocardial oxygen demand (Bauman et al., 1994; O'Leary & Hancox, 2010). Additionally,
the blockage of the voltage-gated sodium channels has also been implicated in COC-
induced heart damage (Afonso et al., 2007; Awtry & Philippides, 2010; Hollander, 2008).
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Although cardiotoxicity of COC have traditionally been attributed to sympathomimetic
stimulation, compelling evidence proved that COC and its metabolites may exert direct
toxicity (Valente et al., 2012; Welder, Smith, Ramos, & Acosta, 1988; Xu, Flick, Mitchel,
Knowles, & Ault, 1999).
So, in the current work we chose to evaluate the toxicity of a few mixtures of COC
in two in vitro models for the hepatocyte and cardiomyocyte, namely primary hepatocytes
isolated from rat liver and immortalized H9c2 rat cells, respectively.
H9c2 cells have been widely used in toxicity studies as a useful in vitro model for
the cardiomyocyte (Arbo et al., 2014; Begieneman et al., 2016; Sardao, Oliveira, Holy,
Oliveira, & Wallace, 2007). These cells display morphological features similar to those of
immature embryonic cardiomyocytes but maintain several biochemical characteristics of
adult cardiomyocytes (Hescheler et al., 1991); they form confluent multinuclear cells
(myotubes) and present electrical and signalling mechanisms characteristic of cardiac cell
(Kimes & Brandt, 1976). The L-type voltage-dependent calcium channels and the pattern
of signal-transducing G proteins of H9c2 cells are cardiac-specific. They are rich in rough
endoplasmic reticulum, the cell surface is often enlarged by microvilli, and its sugar residues
coating is similar to that found in isolated rat cardiomyocytes (Hescheler et al., 1991). These
cells express genes encoding for cardiac sarcomeric proteins, such as troponin T, calcium
transporters and associated machinery (Branco et al., 2015).
In what concerns our choice regarding the hepatic model, primary hepatocytes
remain the gold standard for liver in vitro toxicity studies. Compared to the established cell
lines, primary hepatocytes are more representative of the in vivo situation, as they possess
the same phenotypic and genotypic characteristics. Contrary, most currently used liver-
derived immortalized cells, such as HepG2, are derived from hepatic tumours and display
an altered expression profile of liver-specific functions (Gerets et al., 2012). Due to the high
proliferative capacity of these cells, the expression profile of many liver-specific genes has
been shown to vary between passages and, consequently, data from immortalized
hepatocytes may lack reproducibility and consistency across laboratories or among
experiments set in different occasions. Still, considering the drawbacks of using primary
cells (limited life span, low throughput, animal ethical concerns, costs associated to animal
maintenance and care, inter-individual variability and, consequently, low reproducibility), we
pondered for our study the use of a recently developed human hepatoma cell line, HepaRG
cells, as it retains high expression of many liver-specific functions, such as cytochrome
P450s, nuclear receptors, transcription, membrane transporters, and phase II enzymes
(Gerets et al., 2012). Unfortunately, these cells were established from a donor who was
CYP2E1 and CYP2D6 poor metabolizer, and these CYP450 isoforms are very important
for the metabolism of our testing drugs (Carmo et al., 2006 ; Koop & Tierney, 1990).
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Our results from H9c2 cardiomyocyte exposures show that MDMA (EC50 1.07 mM)
was the most toxic drug. Previously, Carvalho et al (2004) observed no toxicity when freshly
isolated adult rat cardiomyocytes were exposed to MDMA for 4 h, at concentrations up to
1.6 mM. In the same work, these authors proved that MDMA metabolic activation was
required for the manifestation of MDMA in vitro cardiotoxicity. It is possible that in our work
the longer incubation with the drug could compensate the relatively low metabolic
competence of the heart, as toxicity was expressed at lower concentrations than those
tested by Carvalho et al. This hypothesis is supported by the higher detrimental effects
observed for MDMA in primary hepatocytes (EC50 0.56 mM) – higher metabolic rates are
admitted for this cellular model. The hepatotoxicity observed herein for MDMA was slightly
lower than that previously reported (EC50 1.070 mM) at similar experimental settings
(Valente et al., 2016).
Contrarily, EtOH was the least potent drug in inducing cell death, both in H9c2 (EC50
305.26 mM) and in primary hepatocytes (EC50 263.26 mM). Some discrepancies exist
regarding former reported toxicities; one study describes that 50 mM EtOH reduced viability
of cultured primary rat hepatocytes to ~80%, only after 5h-incubation (Collin et al., 2014),
while another one performed in cultured human hepatocytes more closely resemble our
data (EC50 330 mM; LDH assay after 24 h-incubation). Other studies on the mode of cell
death, showed that EtOH concentrations up to 100 mM induced apoptosis in a
concentration-dependent manner, while from 200 mM on cardiomyocytes isolated from
Sprague-Dawley rats preferentially died by necrosis, when treated for 24 h (Guan, Lui,
Morkin, & Bahl, 2004). These hepatic and cardiac effects seem to be mediated by tumour
necrosis factor-alpha (TNF-α) since increased levels of TNF-α receptor-1 (TNF-R1) were
observed after 24 h-exposure to EtOH, both in rat hepatoma cells (90% at 50 mM and 230%
at 100 mM) and in neonatal rat primary cardiomyocytes (36% at 50 mM and 44% at 100
mM).
Also COC was ~2.4 times less detrimental for H9c2 cells (EC50 2.60 mM), when
compared to primary hepatocytes (EC50 1.07 mM). Few studies offered evidence that in
vitro cell death elicited by COC significantly varies across distinct cellular models and
experimental settings (Jover, Ponsoda, Gomez-Lechon, & Castell, 1993; LeDuc et al., 1994;
Zaragoza, Diez-Fernandez, Alvarez, Andres, & Cascales, 2001). For instance, slight LDH
leakage was observed when neonatal Sprague-Dawley rat myocardial cells where exposed
to 1 mM COC for 24 h (Yuan & Acosta, 2000), but that concentration was close to the EC50
observed for hepatocytes isolated from male Sprague-Dawley (EC50 1.10 mM), which is in
line with our findings (Jover et al., 1993).
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Compared to the other drugs, the lower cardiotoxicity of MORPH (EC50 6.93 mM)
may be related to the H9c2 protective effects that were described for this drug, when present
at low concentrations (Amini-Khoei et al., 2016).
Curiously, in what concerns HER hepatotoxicity (EC50 0.26 mM), our data do not
reproduce results from other assays in cultured human hepatocytes, in which toxicity after
24 h incubation was only achieved at higher concentrations (EC50 3.6 mM for LHD assay;
EC50 3.9 mM for MTT assay) (Jover et al., 1993). Although some interspecies variability
might be at play, in addition to the fact that extremely different cell culture conditions were
used by the authors of this study, we acknowledge that these differences are very
significant.
In general, with exception of MORPH and HER, which were only tested in one
cellular model and therefore comparisons are precluded, all tested drugs disclosed higher
toxicity in primary hepatocytes. These data suggest that the functional specificity of the
organ from which cells derive might be implicated in the toxicological discrepancies
observed. Of particular interest, metabolism may present relevant implications for the
expression of toxicity in hepatocytes where the levels of enzymes are more preponderant;
even in the absence of metabolic activation (such as the cases of MDMA, COC, and EtOH,
whose metabolites are more detrimental than the parent drugs), the metabolic pathways
involved in the detoxification processes are great generators of ROS/RNS (e.g. NADPH
oxidase activity). In the same way, drugs that more extensively affect calcium signalling
pathways will probably impact cardiomyocyte more severely; for example, COC inhibits
inwardly rectifying potassium channels activated by G protein (GIRK, Kir3), impairing
regulation of cardiomyocyte excitability and contractility; EtOH has the opposite action
(Kobayashi, Nishizawa, & Ikeda, 2011).
In addition, the differential expression of CYP isoforms across distinct species can
be responsible for differences in susceptibility to the drug toxicity (Pellinen et al., 2000). For
instance, in mouse, CYP2A, 2B, and 3A have been shown to catalyse COC N-
demethylation (Aoki, Takimoto, Ota, & Yoshida, 2000; Bornheim, 1998; Pellinen et al., 1994;
Pellinen et al., 1996). This reaction is catalysed by CYP3A and CYP2B in rat, and by CYP3A
in humans (Boelsterli, Lanzotti, Goldlin, & Oertle, 1992; LeDuc et al., 1993; A. P. Li,
Kaminski, & Rasmussen, 1995; Pellinen et al., 1994; Poet, Brendel, & Halpert, 1994; Poet,
McQueen, & Halpert, 1996). These interspecies metabolic differences were connected to
differences observed in liver damage. Comparing the three species, mouse and human are
the most and the least sensible specie to COC hepatotoxicity, respectively (Connors et al.,
1990).
Owing information on toxicity for the single drugs, we were then able to proceed to
the mixture assessments. One of our main motivations for these mixture studies was to
PART V: DISCUSSION
60
address the concern that toxicological profiling of single drugs might grossly underestimate
combined toxicity due to the potential for occurrence of synergism or additivity between
mixture components, such has been observed for other drugs of abuse (e.g. amphetamine-
and piperazine-derivatives) (Antia, Tingle, & Russell, 2009a, 2009b; da Silva et al., 2014;
Dias da Silva et al., 2016).
The assessment of the combination effects in terms of synergy, antagonism and
additivity, relies on the accurate prediction of the expected mixture effects. When we started
our investigations, most of the studies conducted with COC and their associations, including
those claiming synergisms {Duvauchelle, 1998 #1196; Aberg, 2007 #1189; Sobel, 1999
#1122; Cunha-Oliveira, 2010 #1170; Czoty, 2015 #1124; Daza-Losada, 2008 #1177; {Diller,
2007 #1187} were designed with no reference to the expected joint effects, nor to the
conceptual principles, such as the CA and IA, which are the foundation of mixture additivity.
Also, all too often, mixture expectations were inaccurately set, for example by admitting
‘effect summation’ (Duvauchelle, Sapoznik, & Kornetsky, 1998).
In what concerns the prediction models used herein, it is generally accepted that CA
produces accurate estimations of the effects of mixtures containing drugs that act by similar
mechanisms; therefore, each individual drug will contribute to the overall mixture effect in
proportion to its concentration. So, it is expectable that when one mixture component is
replaced by an equieffective concentration of another one, the same overall effect will be
observed. Contrarily, the IA model produces more robust predictions for mixtures of drugs
that have distinct mechanisms of action; also, it has been successfully applied to mixtures
of drugs whose mechanisms are unknown (Cedergreen et al., 2008). Notwithstanding, it
often happens that CA and IA generate very identical expectations of additive mixture
effects, which cannot be distinguished from one another. Examples of this problem were
found when we tested our binary mixtures of COC with commonly consumed drugs.
Accordingly, the effect predictions derived from CA and IA for the six mixtures tested were
not sufficiently different to enable choosing the most accurate model for prediction of
mixture effects – although CA demonstrated to be a model slightly more conservative and,
therefore, more protective, as its EC50 values were marginally smaller than those achieved
for IA.
It has been shown that the discrimination between predictions derived from CA and
IA relies on the number of the components of the mixture, their fraction in the mixture, and
on the slopes of their concentration-response fits (Drescher & Boedeker, 1995). Thus, in
our study, in order to validate the applicability of these models, one of the following
approaches would have to be considered: i) selection of a different regression model for
describing the relationships concentration versus effects of the single agents, or changing
the in vitro system used (e.g. other cellular model) in order to alter the slope of the individual
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drugs; ii) changing the mixture ratios; or iii) increasing the number of mixture components.
Even tough, none of these strategies would assure clear distinction between CA and IA. In
addition, all settings of our experiments were meticulously selected; for instance, the choice
of the nonlinear regressions to fit experimental data was based on best fit statistical criteria,
the combination ratios were based on mixtures that occurred in realistic situations, and by
using binary mixtures we intended to reduce the complexity and the confounding factors
associated with the toxicological assessment of mixtures.
Regarding the deviations from additivity reported in this work, experimental effects
obtained for Mix A in primary rat hepatocytes were shifted to left, compared to the computed
expectations, and are therefore consistent with antagonism. Previous studies demonstrated
that in humans the hydrolyses of HER to 6-MAM, and of 6-MAM to morphine by liver PChE
and carboxylesterases hCE1 and hCE2 are competitively inhibited by COC (Kamendulis et
al., 1996). Since the prediction models that we used to assess mixture toxicity do not take
into account pharmacokinetic or pharmacodynamic interactions, and the metabolism of
these two drugs is catalysed by common enzymatic pathways in liver, it is plausible that the
occurrence of metabolic competition could result in the antagonism here reported, since
COC metabolites were demonstrated to be highly toxic (Boelsterli & Goldlin, 1991; Valente
et al., 2012).
Contrary to Mix A, a synergism was verified for Mix C and it may also be explained
by the occurrence of metabolic interactions. Accordingly, studies in humans showed that
plasma concentrations of benzoylecgonine decrease in the drug combination settings, while
COC concentrations increase (Cami, Farre, Gonzalez, Segura, & de la Torre, 1998). This
strongly supports the hypothesis of liver carboxylesterases inhibition; COC is metabolized
to benzoylecgonine by the action of liver hCE1; in the presence of EtOH, the
carboxylesterase catalyses the ethyl transesterification of COC into CE; of note, the active
metabolites CE and norcocaethylene were only observed in the mixture settings (Cami et
al., 1998) and CE has lower binding affinity to the esterase, leading to a longer elimination
half-life (Brzezinski et al., 1997). On the other hand, the pathway of NCOC formation
through CYP 3A4 seems to be privileged in the presence of EtOH, as plasma concentrations
of NCOC were higher for the mixture administration (Cami et al., 1998). As mentioned,
NCOC is metabolized to the free radical NCOC-NO. (Pellinen et al., 2000), which induces
intense oxidative stress and ultimately impairs the hepatocellular function (Charkoudian &
Shuster, 1985). Consequentially, the differential profile of metabolites that arise from the
combination may severely alter the overall hepatotoxicity, when these drugs co-occur.
For Mix D, the effects observed in hepatocytes seem to be dependent on the mixture
concentration; at low concentrations, MDMA and COC seem to interact antagonistically; the
opposite occurs above the EC50, when lower concentrations than predicted were required
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to produce the same effect (i.e. synergism). Interestingly, a similar complex concentration-
dependent pattern of mixture effects had been previously observed, when Diller and
colleagues (2007) measured behavioural and neurochemical effects of MDMA and COC in
combination. These authors reported that increasing doses of COC resulted in antagonistic
CPP effects, when MDMA was at lower doses; but this pattern of antagonism was reversed
at higher doses of MDMA. In this report, pharmacodynamic interactions might be underlying
mixture effects, since COC and MDMA trigger similar dopaminergic mechanisms (Rothman
& Baumann, 2003). In our study, however, pharmacokinetic interactions are more feasible;
COC inhibits CYP2D6 (Shen et al., 2007), the CYP450 isoform that catalyses ~30% MDMA
metabolism (Schmid et al., 2016) and whose polymorphism may severely impact the
expression of MDMA toxicity (Carmo et al., 2006). Another noticeable aspect of Mix D
results is the steeper slope of the experimental curve, compared to the slope of the CA and
IA predictions. Concentration-mortality curves presenting such slopes are of utmost
toxicological relevance, as it indicates that very slight increases in the concentration of the
mixture promote significant increments in cytotoxicity, which may quickly shift from roughly
undetectable to maximal mortality (Dias da Silva, Silva, & Carmo, 2013).
With the exception of the combination with EtOH (Mix C), the toxicity of COC binary
mixtures was potentiated in H9c2 cells, as the drug acted synergistically both with MDMA
(Mix D) and MOR (Mix B). Duvauchelle et al (1998) advocated the synergic reinforcing
effects of COC and MOR diacetate combinations when they observed higher number of
reinforcements for the combination, compared with each drug alone. Although we
acknowledge the relevance of the reported effects, caution should be taken by the authors
when declaring synergisms; in the work cited no reference to the expected effects was done
and, since the dose-response curves did not follow a linear pattern, the ‘effect summation’
concept is not applied. As far as we concerned, the observed effects may also be consistent
with antagonism or additivity. Chemical interactions between these drugs, such as COC-
MOR adduct formation have been strongly debated (Cunha-Oliveira et al., 2010; Garrido et
al., 2007). COC-MOR adducts impair the interaction of the single drugs with the respective
molecular targets (e.g. efflux/ influx transporters, receptors, enzymes, etc.) and may trigger
different signalling pathways. Compared to liver, such adducts are more likely to be
produced in heart, were the drugs are less metabolised or at a slower rate. These
mechanisms of adduct formation may contribute for the interaction that we report herein for
Mix B. In addition, Cunha-Oliveira et al. (2010) demonstrated that when COC and HER
(rapidly converted to MOR) are co-exposed they elicit more neurotoxicity than each drug
alone and the mode of co-exposure [i.e. sequential (HER followed by COC) or simultaneous
(HER: COC)] changed the cell death pathways triggered by the single drugs; in case of
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HER:COC, cell death mechanisms were shifted towards necrosis, which is extremely more
harmful than apoptosis.
The synergism observed for Mix D might be a result of the overlapping mechanisms
of cardiac injury triggered by both COC and MDMA, which include induction of oxidative
stress (Graziani et al., 2016; Song, Moon, Upreti, Eddington, & Lee, 2010) with consequent
modulation of redox-sensitive signalling pathways, such as mitogen-activated protein
kinase (MAPK) superfamily (Fan et al., 2009; Koczor et al., 2015). In agreement, COC
activates MAPKs, in particular extracellular signal-regulated kinase (ERK) 1/2, p38 MAPK,
and c-Jun NH2-terminal kinase phosphorylation, through increased Nox2 oxidase activity
(Fan et al., 2009). Activation of ERK / PI3K/ Akt signal transduction pathways were also
observed following MDMA exposure (Goni-Allo et al., 2008; Koczor et al., 2015). In addition,
recent evidence also involved the modulation of ATP-sensitive potassium (KATP) channels
in the toxicity expressed MDMA and COC (Goni-Allo et al., 2008; Reyes, Kane, Zingman,
Yamada, & Terzic, 2009).
For Mix C, the effects experimentally obtained were in agreement with values
estimated by CA and IA models (additivity). Similarly, when isolated cardiomyocytes were
exposed to COC and ETOH concomitantly, significant greater inhibitory effects on
contractility and on calcium transient amplitude were observed, compared to either drug
alone, and these results were consistent with the additive predictions calculated assuming
that drugs acted independently at distinct targets within the excitation-contraction coupling
pathway (Nicolas, Rubin, & Thomas, 1996). In spite of the existence of other reports of
additivity between COC and EtOH, in our opinion these studies provided no evidence of
such effects (Uszenski, Gillis, Schaer, Analouei, & Kuhn, 1992).
Also, although metabolic interactions have been mostly highlighted as the reason
for experimental deviations from our additivity expectations, particularly in hepatocyte, other
causes should be considered, such as the competition at other drug targets (e.g.
transcription factors, P-glycoprotein efflux pump, membrane receptors, etc.), fraction bound
to serum proteins or retained in the lipid bilayer membrane, which might decrease as it is
displaced from the binding sites by the remaining mixture components, differences
concerning immortalised versus primary cells, etc.
As depicted through this dissertation, the formation of reactive species is one of the
most prominent toxicity mechanisms for the drugs tested herein (Costa, Carvalho, Duarte,
Bastos Mde, & Remiao, 2013). Accordingly, our experimental results demonstrated a
concentrations-dependent increase in ROS/RNS for all drugs (COC, MOR, MDMA and
EtOH), individually or combined. In accordance, oxidative stress was linked to
cardiomyopathy induced by EtOH, through the accumulation of acetaldehyde, which is
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highly reactive and attacks several vital cell structures, such as mitochondria (Guo & Ren,
2010 ; Niemela, 2007; Vendemiale et al., 2001).
In heart, the production of reactive species by modulators of serotonergic and
dopaminergic functions (such as COC and MDMA) is generally explained by the elevation
of catecholamines and, subsequently, either by the stimulation of adrenoreceptors, or by
the enzymatic/ non enzymatic degradation of catecholamines. In our in vitro system,
however, cultured cardiomyocytes are devoid of enervation, hormonal control, and influence
of local biological factors, which improves the mechanistic investigation of direct drug-
induced cardiotoxicity; thus, the contribution of these mechanisms for COC cardiotoxicity
were here abolished and the oxidative stress generated only attributed to the direct
cardiotoxic actions of these drugs (COC, MDMA, MOR, and EtOH).
Nevertheless, significant oxidative stress was only evident at the highest
concentration tested (EC60, p<0.0001), suggesting that oxidative phenomena might be
counteracted by the intrinsic machinery of cellular defence, at lower concentrations; for
example, GSH is a cytosolic redox buffer which displays a pivotal role in cell defence against
redox injury (Griffith, 1999). Binary mixtures of COC with MOR or with EtOH, and the
respective single drugs, decrease cytosolic GSH and, concurrently, promoted a slight
increase of GSSG. These observations are corroborated by studies in rat heart after chronic
COC administration (Fineschi et al., 2001). In vitro experimental data demonstrated that
incubation of isolated adult rat cardiomyocytes with MDMA metabolites decreased GSH
levels and antioxidant enzyme activities, with loss of normal cell morphology (Carvalho et
al., 2004); and Shenouda et al. (2008) observed an increase in nitrated tyrosine residues,
which is as a marker of oxidative stress. However, in our study GSH/GSSG levels were not
evaluated for MDMA nor Mix D.
As a high cytosolic GSH/GSSG ratio is important for cellular antioxidant homeostasis
(Neri et al., 2007), it is conceivable that GSSG is being extruded to the extracellular
environment. On the other hand, the discrepant high depletion of GSH, compared to the
slight GSSG increase, may occur by formation of adducts, such was already reported for
metabolites of MDMA, COC and EtOH (Blair, 2006; Cole & Deeley, 2006; Hiramatsu,
Kumagai, Unger, & Cho, 1990; Sultana, Bhupanapadu Sunkesula, Sharma, Reddanna, &
Babu, 2005).
The excessive generation of reactive species promotes an irreversible modification
of lipids and proteins, compromising the function of vital cell structures such as enzymes,
membranes and transporters. In vivo studies with COC demonstrated the increase of
malondialdehyde (indicative of oxidative damage to cell membranes), GSSG, and protein
carbonyls; and decreased of GSH, manganese superoxide dismutase (MnSOD)
responsible for removing the superoxide anion radical and converting it into hydrogen
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peroxide (H2O2), glutathione peroxidase (GPX) which convert this by-product into water,
catalase, and glutathione-S-transferase (GST) (Costa et al., 2011 ; Neri et al., 2007). In in
vivo studies conducted in adult mice treated with EtOH for six hours, myocardial
ultrastructure alterations, possible caused by myocardial lipid peroxidation and protein
oxidation, were also observed (Kannan, Wang, & Kang, 2004).
The cellular structure and functional integrity may be compromised by reactive
species when cell defence capability is surpassed, as these entities will interact with critical
biologic molecules, such as lipids, nucleic acids, and proteins, promoting the oxidative
degradation. Also, excessive formation of reactive species can affect the production of ATP
by impairing oxidative phosphorylation in mitochondrial electron transport through
deregulation of Ca2+ sequestration in the matrix mitochondrial and disruption of Δψm (GM,
2000). Our experimental results are in line with these mechanisms as mitochondrial
membrane hyperpolarization and a significant decline of ATP levels were observed.
Mitochondrial injury by its turn increases the membrane permeability of the organelle with
consequent release of pro-apoptotic factors. Besides impacting cellular metabolic functions,
ATP levels decide the fate of the cell towards necrosis or apoptosis (energy-dependent
process), corroborating our observations of the altered cell morphology. In vitro studies
demonstrated that cardiomyocytes exposed to EtOH for 24 h died by apoptosis at lower
doses, and by necrosis at higher; these effects were mediated by intracellular increase of
ROS and decrease of mitochondrial membrane potential (S. Y. Li et al., 2006).
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6. Conclusion
The toxicological assessment of mixtures is generally obstructed by the
overwhelming amount of conceivable combinations to which individuals might be exposed
to. Coherently, the use of predictive models to calculate the effects of combinations of
chemicals, using information on toxicity of the individual drugs, would be of relevant
application. Herein, we applied for the first time the concepts of CA and IA to evaluate the
joint effects of COC and a number of frequently co-consumed substances – HER/MOR,
MDMA, and EtOH – that are known to be concomitantly ingested, in corresponding
recreational scene. Of concern, the toxicological impact of the co-occurrence of COC and
these substances could hardly be anticipated by these two broadly employed models for
the calculation of mixture effects of chemicals. Our predictions according to these principles,
which are widely used for estimating toxicity of chemical mixtures in several fields, proved
to be inadequate for the appraisal of the joint effects of mixtures of COC. This conclusion
hold true when several binary mixtures of the drug were tested at realist drug ratios, in two
different in vitro systems that are representative of major target organs for the toxicity of this
drug, i.e. liver and heart. All observed deviations from additivity probably indicate that
pharmacokinetic interactions are at play.
Notably, several additive effects that conformed to CA and synergisms were
observed, denoting that the co-occurrence of other drugs greatly altered COC individual
toxicity. Both manifestations are worrisome and, in a clinical perspective, may imply
important toxicological consequences for the consumer. Overall, our results emphasize the
risks at which consumers of these drugs are exposed to, when engaging in polydrug abuse
practices.
Evidence from our work also indicates that the effects of a particular mixture might
be significantly different among the distinct target organs, suggesting that, depending on
their functional specificity, differential mechanisms of toxicity or protection might be at play.
As hepatocytes revealed greater susceptibility to individual and combined drug-induced
toxicity, compared to H9c2 cardiomyocytes, and admitting that this model is metabolically
more competent, this might indicate that cells are more vulnerable when exposed to
substances that are metabolised into harmful metabolites.
The mechanistic evaluation on the pathways triggered by these drugs and their
mixtures revealed that increase oxidative stress with concurrent decline of antioxidant
defences, dramatic depletion of intracellular ATP, and hyperpolarization of mitochondria
might be strongly correlated to the observed cardiomyocyte toxicity.
PART VII: REFERENCES
68
PART VII
REFERENCES
PART VII: REFERENCES
69
7. References
Aberg, M., Wade, D., Wall, E., & Izenwasser, S. (2007). Effect of MDMA (ecstasy) on activity
and cocaine conditioned place preference in adult and adolescent rats. Neurotoxicol
Teratol, 29(1), 37-46.
Achat-Mendes, C., Anderson, K. L., & Itzhak, Y. (2003). Methylphenidate and MDMA
adolescent exposure in mice: long-lasting consequences on cocaine-induced
reward and psychomotor stimulation in adulthood. Neuropharmacology, 45(1), 106-
115.
Afonso, L., Mohammad, T., & Thatai, D. (2007). Crack whips the heart: a review of the
cardiovascular toxicity of cocaine. Am J Cardiol, 100(6), 1040-1043.
Altenburger, R., Backhaus, T., Boedeker, W., Faust, M., Scholze, M., & Grimme, L. H.
(2000). Predictability of the toxicity of multiple chemical mixtures to Vibrio fischeri:
Mixtures composed of similarly acting chemicals. Environmental Toxicology and
Chemistry, 19(9), 2341-2347.
Amini-Khoei, H., Hosseini, M. J., Momeny, M., Rahimi-Balaei, M., Amiri, S., Haj-Mirzaian,
A., . . . Dehpour, A. R. (2016). Morphine Attenuated the Cytotoxicity Induced by
Arsenic Trioxide in H9c2 Cardiomyocytes. Biol Trace Elem Res, 173(1), 132-139.
Andersson, M., Bjorkhem-Bergman, L., & Beck, O. (2015). Possible mechanism for
inhibition of morphine formation from 6-acetylmorphine after intake of street heroin.
Forensic Sci Int, 252, 150-156.
Antia, U., Tingle, M. D., & Russell, B. R. (2009a). In vivo interactions between BZP and
TFMPP (party pill drugs). N Z Med J, 122(1303), 29-38.
Antia, U., Tingle, M. D., & Russell, B. R. (2009b). Metabolic interactions with piperazine-
based 'party pill' drugs. J Pharm Pharmacol, 61(7), 877-882.
Antolino-Lobo, I., Meulenbelt, J., Nijmeijer, S. M., Maas-Bakker, R. F., Meijerman, I., van
den Berg, M., & van Duursen, M. B. (2011). 3,4-methylenedioxymethamphetamine
(MDMA) interacts with therapeutic drugs on CYP3A by inhibition of pregnane X
receptor (PXR) activation and catalytic enzyme inhibition. Toxicol Lett, 203(1), 82-
91.
Aoki, K., Takimoto, M., Ota, H., & Yoshida, T. (2000). Participation of CYP2A in cocaine-
induced hepatotoxicity in female mice. Pharmacol Toxicol, 87(1), 26-32.
Arbo, M. D., Silva, R., Barbosa, D. J., da Silva, D. D., Rossato, L. G., Bastos Mde, L., &
Carmo, H. (2014). Piperazine designer drugs induce toxicity in cardiomyoblast h9c2
cells through mitochondrial impairment. Toxicol Lett, 229(1), 178-189.
Aslibekyan, S., Levitan, E. B., & Mittleman, M. A. (2008). Prevalent cocaine use and
myocardial infarction. Am J Cardiol, 102(8), 966-969.
PART VII: REFERENCES
70
Awtry, E. H., & Philippides, G. J. (2010). Alcoholic and cocaine-associated
cardiomyopathies. Prog Cardiovasc Dis, 52(4), 289-299.
Bailey, D. N. (1994). Studies of cocaethylene (ethylcocaine) formation by human tissues in
vitro. J Anal Toxicol, 18(1), 13-15.
Bauman, J. L., Grawe, J. J., Winecoff, A. P., & Hariman, R. J. (1994). Cocaine-related
sudden cardiac death: a hypothesis correlating basic science and clinical
observations. J Clin Pharmacol, 34(9), 902-911.
Begieneman, M. P., Ter Horst, E. N., Rijvers, L., Meinster, E., Leen, R., Pankras, J., . . .
Krijnen, P. A. (2016). Dopamine induces lipid accumulation, NADPH oxidase-related
oxidative stress and a pro-inflammatory status of the plasma membrane in H9C2
cells. Am J Physiol Heart Circ Physiol
Blair, I. A. (2006). Endogenous glutathione adducts. Curr Drug Metab, 7(8), 853-872.
Boelsterli, U. A., & Goldlin, C. (1991). Biomechanisms of cocaine-induced hepatocyte injury
mediated by the formation of reactive metabolites. Arch Toxicol, 65(5), 351-360.
Boelsterli, U. A., Lanzotti, A., Goldlin, C., & Oertle, M. (1992). Identification of cytochrome
P-450IIB1 as a cocaine-bioactivating isoform in rat hepatic microsomes and in
cultured rat hepatocytes. Drug Metab Dispos, 20(1), 96-101.
Bornheim, L. M. (1998). Effect of cytochrome P450 inducers on cocaine-mediated
hepatotoxicity. Toxicol Appl Pharmacol, 150(1), 158-165.
Bortolotti, F., Gottardo, R., Pascali, J., & Tagliaro, F. (2012). Toxicokinetics of cocaine and
metabolites: the forensic toxicological approach. Curr Med Chem, 19(33), 5658-
5663.
Branco, A. F., Pereira, S. P., Gonzalez, S., Gusev, O., Rizvanov, A. A., & Oliveira, P. J.
(2015). Gene Expression Profiling of H9c2 Myoblast Differentiation towards a
Cardiac-Like Phenotype. PLoS One, 10(6), e0129303.
Brown, E., Prager, J., Lee, H. Y., & Ramsey, R. G. (1992). CNS complications of cocaine
abuse: prevalence, pathophysiology, and neuroradiology. AJR Am J Roentgenol,
159(1), 137-147.
Brzezinski, M. R., Spink, B. J., Dean, R. A., Berkman, C. E., Cashman, J. R., & Bosron, W.
F. (1997). Human liver carboxylesterase hCE-1: binding specificity for cocaine,
heroin, and their metabolites and analogs. Drug Metab Dispos, 25(9), 1089-1096.
Caine, S. B., Negus, S. S., Mello, N. K., Patel, S., Bristow, L., Kulagowski, J., Borrelli, E.
(2002). Role of dopamine D2-like receptors in cocaine self-administration: studies
with D2 receptor mutant mice and novel D2 receptor antagonists. J Neurosci, 22(7),
2977-2988.
PART VII: REFERENCES
71
Cami, J., Farre, M., Gonzalez, M. L., Segura, J., & de la Torre, R. (1998). Cocaine
metabolism in humans after use of alcohol. Clinical and research implications.
Recent Dev Alcohol, 14, 437-455.
Caplan, Y. H. (2015). Disposition of toxic drugs and chemicals in man. J Anal Toxicol, 39(5),
417.
Carmo, H., Brulport, M., Hermes, M., Oesch, F., Silva, R., Ferreira, L. M., . . . Hengstler, J.
G. (2006). Influence of CYP2D6 polymorphism on 3,4-
methylenedioxymethamphetamine ('Ecstasy') cytotoxicity. Pharmacogenet
Genomics, 16(11), 789-799.
Carroll, F. I., Gao, Y., Abraham, P., Lewin, A. H., Lew, R., Patel, A., . . . Kuhar, M. J. (1992).
Probes for the cocaine receptor. Potentially irreversible ligands for the dopamine
transporter. J Med Chem, 35(10), 1813-1817.
Carvalho, M., Remiao, F., Milhazes, N., Borges, F., Fernandes, E., Monteiro Mdo, C.,
Bastos, M. L. (2004). Metabolism is required for the expression of ecstasy-induced
cardiotoxicity in vitro. Chem Res Toxicol, 17(5), 623-632.
Cedergreen, N., Christensen, A. M., Kamper, A., Kudsk, P., Mathiassen, S. K., Streibig, J.
C., & Sorensen, H. (2008). A review of independent action compared to
concentration addition as reference models for mixtures of compounds with different
molecular target sites. Environ Toxicol Chem, 27(7), 1621-1632.
Chan, L. N., & Anderson, G. D. (2014). Pharmacokinetic and pharmacodynamic drug
interactions with ethanol (alcohol). Clin Pharmacokinet, 53(12), 1115-1136.
Charkoudian, J. C., & Shuster, L. (1985). Electrochemistry of norcocaine nitroxide and
related compounds: implications for cocaine hepatotoxicity. Biochem Biophys Res
Commun, 130(3), 1044-1051.
Cole, S. P., & Deeley, R. G. (2006). Transport of glutathione and glutathione conjugates by
MRP1. Trends Pharmacol Sci, 27(8), 438-446.
Collin, A., Hardonniere, K., Chevanne, M., Vuillemin, J., Podechard, N., Burel, A., Sergent,
O. (2014). Cooperative interaction of benzo[a]pyrene and ethanol on plasma
membrane remodeling is responsible for enhanced oxidative stress and cell death
in primary rat hepatocytes. Free Radic Biol Med, 72, 11-22.
Cone, E. J., Hillsgrove, M., & Darwin, W. D. (1994). Simultaneous measurement of cocaine,
cocaethylene, their metabolites, and "crack" pyrolysis products by gas
chromatography-mass spectrometry. Clin Chem, 40(7 Pt 1), 1299-1305.
Connors, S., Rankin, D. R., Gandolfi, A. J., Krumdieck, C. L., Koep, L. J., & Brendel, K.
(1990). Cocaine hepatotoxicity in cultured liver slices: a species comparison.
Toxicology, 61(2), 171-183.
PART VII: REFERENCES
72
Costa, V. M., Carvalho, F., Bastos, M. L., Carvalho, R. A., Carvalho, M., & Remiao, F.
(2011). Contribution of catecholamine reactive intermediates and oxidative stress to
the pathologic features of heart diseases. Curr Med Chem, 18(15), 2272-2314.
Costa, V. M., Carvalho, F., Duarte, J. A., Bastos Mde, L., & Remiao, F. (2013). The heart
as a target for xenobiotic toxicity: the cardiac susceptibility to oxidative stress. Chem
Res Toxicol, 26(9), 1285-1311.
Crespi, D., Mennini, T., & Gobbi, M. (1997). Carrier-dependent and Ca(2+)-dependent 5-
HT and dopamine release induced by (+)-amphetamine, 3,4-
methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br J
Pharmacol, 121(8), 1735-1743.
Cunha-Oliveira, T., Rego, A. C., Garrido, J., Borges, F., Macedo, T., & Oliveira, C. R. (2010).
Neurotoxicity of heroin-cocaine combinations in rat cortical neurons. Toxicology,
276(1), 11-17.
Czoty, P. W. (2015). Effects of chronic binge-like ethanol consumption on cocaine self-
administration in rhesus monkeys. Drug Alcohol Depend.
da Silva, D. D., Silva, E., Carvalho, F., & Carmo, H. (2014). Mixtures of 3,4-
methylenedioxymethamphetamine (ecstasy) and its major human metabolites act
additively to induce significant toxicity to liver cells when combined at low, non-
cytotoxic concentrations. J Appl Toxicol, 34(6), 618-627.
Dackis, C. A., & Gold, M. S. (1985). New concepts in cocaine addiction: the dopamine
depletion hypothesis. Neurosci Biobehav Rev, 9(3), 469-477.
Dackis, C. A., & O'Brien, C. P. (2001). Cocaine dependence: a disease of the brain's reward
centers. J Subst Abuse Treat, 21(3), 111-117.
Decorte, T. (2001). Quality control by cocaine users: underdeveloped harm reduction
strategies. European Addiction Research, 7(4), 161-175.
DeMaria, P. A., Jr., Sterling, R., & Weinstein, S. P. (2000). The effect of stimulant and
sedative use on treatment outcome of patients admitted to methadone maintenance
treatment. Am J Addict, 9(2), 145-153.
Dias da Silva, D., Silva, E., & Carmo, H. (2013). Cytotoxic effects of amphetamine mixtures
in primary hepatocytes are severely aggravated under hyperthermic conditions.
Toxicol In Vitro, 27(6), 1670-1678.
Dias da Silva, D., Silva, M. J., Moreira, P., Martins, M. J., Valente, M. J., Carvalho, F.,
Carmo, H. (2016). In vitro hepatotoxicity of 'Legal X': the combination of 1-
benzylpiperazine (BZP) and 1-(m-trifluoromethylphenyl)piperazine (TFMPP)
triggers oxidative stress, mitochondrial impairment and apoptosis. Arch Toxicol.
Diller, A. J., Rocha, A., Cardon, A. L., Valles, R., Wellman, P. J., & Nation, J. R. (2007). The
effects of concurrent administration of +/-3,4-methylenedioxymethamphetamine and
PART VII: REFERENCES
73
cocaine on conditioned place preference in the adult male rat. Pharmacol Biochem
Behav, 88(2), 165-170.
Downey, K. K., Helmus, T. C., & Schuster, C. R. (2000). Treatment of heroin-dependent
poly-drug abusers with contingency management and buprenorphine maintenance.
Exp Clin Psychopharmacol, 8(2), 176-184.
Drescher, K., & Boedeker, W. (1995). Assessment of the Combined Effects of Substances:
The Relationship between Concentration Addition and Independent Action.
Biometrics, 51(2), 716-730.
Duvauchelle, C. L., Sapoznik, T., & Kornetsky, C. (1998). The synergistic effects of
combining cocaine and heroin ("speedball") using a progressive-ratio schedule of
drug reinforcement. Pharmacol Biochem Behav, 61(3), 297-302.
EMCDDA. (2002). 2002 Annual report on the state of the drugs problem in the European
Union and Norway  Polydrug use.
EMCDDA. (2007). Drugs in Focus, Cocaine use in Europe: implications for service delivery
EMCDDA. (2009). Selected issue, Polydrug use: patterns and responses.
EMCDDA. (2012). EMCDDA publishes 2012 report on the state of the drugs problem in
Europe, Eurosurveillance.
EMCDDA. (2015). European drug report - Trends and Development.
Erlich, P. (1890). Studien in der cocanreihe. Deutsch Med. Wochenschr, 16, 717.
Fan, L., Sawbridge, D., George, V., Teng, L., Bailey, A., Kitchen, I., & Li, J. M. (2009).
Chronic cocaine-induced cardiac oxidative stress and mitogen-activated protein
kinase activation: the role of Nox2 oxidase. J Pharmacol Exp Ther, 328(1), 99-106.
Farre, M., de la Torre, R., Gonzalez, M. L., Teran, M. T., Roset, P. N., Menoyo, E., & Cami,
J. (1997). Cocaine and alcohol interactions in humans: neuroendocrine effects and
cocaethylene metabolism. J Pharmacol Exp Ther, 283(1), 164-176.
Farre, M., de la Torre, R., Llorente, M., Lamas, X., Ugena, B., Segura, J., & Cami, J. (1993).
Alcohol and cocaine interactions in humans. J Pharmacol Exp Ther, 266(3), 1364-
1373.
Festa, E. D., Russo, S. J., Gazi, F. M., Niyomchai, T., Kemen, L. M., Lin, S. N., . . .
Quinones-Jenab, V. (2004). Sex differences in cocaine-induced behavioral
responses, pharmacokinetics, and monoamine levels. Neuropharmacology, 46(5),
672-687.
Fineschi, V., Baroldi, G., Centini, F., Cerretani, D., Fiaschi, A. I., Micheli, L., . . . Giorgi, G.
(2001). Markers of cardiac oxidative stress and altered morphology after
intraperitoneal cocaine injection in a rat model. Int J Legal Med, 114(6), 323-330.
PART VII: REFERENCES
74
Freye, E., & Levy, J. V. (2009). Pharmacology and abuse of cocaine, amphetamines,
ecstasy and related designer drugs : a comprehensive review on their mode of
action, treatment of abuse and intoxication. Dordrecht: Springer.
Garfia, A., Valverde, J. L., Borondo, J. C., Candenas, I., & Lucena, J. (1990). Vascular
lesions in intestinal ischemia induced by cocaine-alcohol abuse: report of a fatal
case due to overdose. J Forensic Sci, 35(3), 740-745.
Garrido, J. M., Marques, M. P., Silva, A. M., Macedo, T. R., Oliveira-Brett, A. M., & Borges,
F. (2007). Spectroscopic and electrochemical studies of cocaine-opioid interactions.
Anal Bioanal Chem, 388(8), 1799-1808.
Gatch, M. B., Negus, S. S., Butelman, E. R., & Mello, N. K. (1995). Antinociceptive effects
of cocaine/opioid combinations in rhesus monkeys. J Pharmacol Exp Ther, 275(3),
1346-1354.
Gerets, H. H., Tilmant, K., Gerin, B., Chanteux, H., Depelchin, B. O., Dhalluin, S., &
Atienzar, F. A. (2012). Characterization of primary human hepatocytes, HepG2 cells,
and HepaRG cells at the mRNA level and CYP activity in response to inducers and
their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol, 28(2),
69-87.
Geromel, V., Kadhom, N., Cebalos-Picot, I., Ouari, O., Polidori, A., Munnich, A., Rustin, P.
(2001). Superoxide-induced massive apoptosis in cultured skin fibroblasts harboring
the neurogenic ataxia retinitis pigmentosa (NARP) mutation in the ATPase-6 gene
of the mitochondrial DNA. Hum Mol Genet, 10(11), 1221-1228.
Glauser, J., & Queen, J. R. (2007). An overview of non-cardiac cocaine toxicity. J Emerg
Med, 32(2), 181-186.
GM, C. (2000). The Mechanism of Oxidative Phosphorylation The Cell: A Molecular
Approach (2nd ed.). Sunderland (MA): Sinauer Associates;.
Goldstein, R. A., DesLauriers, C., & Burda, A. M. (2009). Cocaine: history, social
implications, and toxicity--a review. Dis Mon, 55(1), 6-38.
Goni-Allo, B., Puerta, E., Ramos, M., Lasheras, B., Jordan, J., & Aguirre, N. (2008).
Minoxidil prevents 3,4-methylenedioxymethamphetamine-induced serotonin
depletions: role of mitochondrial ATP-sensitive potassium channels, Akt and ERK.
J Neurochem, 104(4), 914-925.
Gossop, M., Griffiths, P., Powis, B., & Strang, J. (1994). Cocaine: patterns of use, route of
administration, and severity of dependence. Br J Psychiatry, 164(5), 660-664.
Gossop, M., Manning, V., & Ridge, G. (2006). Concurrent use and order of use of cocaine
and alcohol: behavioural differences between users of crack cocaine and cocaine
powder. Addiction, 101(9), 1292-1298.
PART VII: REFERENCES
75
Grant, B. F., & Harford, T. C. (1990). Concurrent and simultaneous use of alcohol with
cocaine: results of national survey. Drug Alcohol Depend, 25(1), 97-104.
Graziani, M., Antonilli, L., Togna, A. R., Grassi, M. C., Badiani, A., & Saso, L. (2016).
Cardiovascular and Hepatic Toxicity of Cocaine: Potential Beneficial Effects of
Modulators of Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2016,
8408479.
Griffith, O. W. (1999). Biologic and pharmacologic regulation of mammalian glutathione
synthesis. Free Radic Biol Med, 27(9-10), 922-935.
Guan, Z., Lui, C. Y., Morkin, E., & Bahl, J. J. (2004). Oxidative stress and apoptosis in
cardiomyocyte induced by high-dose alcohol. J Cardiovasc Pharmacol, 44(6), 696-
702.
Guo, R., & Ren, J. (2010). Alcohol dehydrogenase accentuates ethanol-induced myocardial
dysfunction and mitochondrial damage in mice: role of mitochondrial death pathway.
PLoS One, 5(1), e8757.
Harris, D. S., Everhart, E. T., Mendelson, J., & Jones, R. T. (2003). The pharmacology of
cocaethylene in humans following cocaine and ethanol administration. Drug Alcohol
Depend, 72(2), 169-182.
Hatsukami, D. K., & Fischman, M. W. (1996). Crack cocaine and cocaine hydrochloride.
Are the differences myth or reality? Jama, 276(19), 1580-1588.
He, Y. J., Brockmoller, J., Schmidt, H., Roots, I., & Kirchheiner, J. (2008). CYP2D6
ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or
heroin? J Anal Toxicol, 32(2), 178-182.
Heard, K., Palmer, R., & Zahniser, N. R. (2008). Mechanisms of acute cocaine toxicity.
Open Pharmacol J, 2(9), 70-78.
Helzer, J. E., & Pryzbeck, T. R. (1988). The co-occurrence of alcoholism with other
psychiatric disorders in the general population and its impact on treatment. J Stud
Alcohol, 49(3), 219-224.
Hescheler, J., Meyer, R., Plant, S., Krautwurst, D., Rosenthal, W., & Schultz, G. (1991).
Morphological, biochemical, and electrophysiological characterization of a clonal
cell (H9c2) line from rat heart. Circ Res, 69(6), 1476-1486.
Hiramatsu, M., Kumagai, Y., Unger, S. E., & Cho, A. K. (1990). Metabolism of
methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a
quinone identified as its glutathione adduct. J Pharmacol Exp Ther, 254(2), 521-527.
Hollander, J. E. (2008). Cocaine intoxication and hypertension. Ann Emerg Med, 51(3
Suppl), S18-20.
Hudgins, R., McCusker, J., & Stoddard, A. (1995). Cocaine use and risky injection and
sexual behaviors. Drug Alcohol Depend, 37(1), 7-14.
PART VII: REFERENCES
76
Hunt, D. E., Lipton, D. S., Goldsmith, D., & Strug, D. (1984). Street pharmacology: uses of
cocaine and heroin in the treatment of addiction. Drug Alcohol Depend, 13(4), 375-
387.
Itzhak, Y., & Ali, S. F. (2006). Role of nitrergic system in behavioral and neurotoxic effects
of amphetamine analogs. Pharmacol Ther, 109(1-2), 246-262.
Jeffcoat, A. R., Perez-Reyes, M., Hill, J. M., Sadler, B. M., & Cook, C. E. (1989). Cocaine
disposition in humans after intravenous injection, nasal insufflation (snorting), or
smoking. Drug Metab Dispos, 17(2), 153-159.
Jenkins, A. J., Levine, B., Titus, J., & Smialek, J. E. (1999). The interpretation of cocaine
and benzoylecgonine concentrations in postmortem cases. Forensic Sci Int, 101(1),
17-25.
Jenkins, A. J., Oyler, J. M., & Cone, E. J. (1995). Comparison of heroin and cocaine
concentrations in saliva with concentrations in blood and plasma. J Anal Toxicol,
19(6), 359-374.
Jover, R., Ponsoda, X., Gomez-Lechon, J., & Castell, J. V. (1993). Cocaine hepatotoxicity:
two different toxicity mechanisms for phenobarbital-induced and non-induced rat
hepatocytes. Biochem Pharmacol, 46(11), 1967-1974.
Joya, X., Friguls, B., Simo, M., Civit, E., de la Torre, R., Palomeque, A., Garcia-Algar, O.
(2011). Acute heroin intoxication in a baby chronically exposed to cocaine and
heroin: a case report. J Med Case Rep, 5, 288. doi: 10.1186/1752-1947-5-288
Jufer, R. A., Wstadik, A., Walsh, S. L., Levine, B. S., & Cone, E. J. (2000). Elimination of
cocaine and metabolites in plasma, saliva, and urine following repeated oral
administration to human volunteers. J Anal Toxicol, 24(7), 467-477.
Kamendulis, L. M., Brzezinski, M. R., Pindel, E. V., Bosron, W. F., & Dean, R. A. (1996).
Metabolism of cocaine and heroin is catalyzed by the same human liver
carboxylesterases. J Pharmacol Exp Ther, 279(2), 713-717.
Kampman, K. M., Pettinati, H. M., Lynch, K. G., Spratt, K., Wierzbicki, M. R., & O'Brien, C.
P. (2013). A double-blind, placebo-controlled trial of topiramate for the treatment of
comorbid cocaine and alcohol dependence. Drug Alcohol Depend, 133(1), 94-99.
Kanel, G. C., Cassidy, W., Shuster, L., & Reynolds, T. B. (1990). Cocaine-induced liver cell
injury: comparison of morphological features in man and in experimental models.
Hepatology, 11(4), 646-651.
Kannan, M., Wang, L., & Kang, Y. J. (2004). Myocardial oxidative stress and toxicity induced
by acute ethanol exposure in mice. Exp Biol Med (Maywood), 229(6), 553-559.
Karch, S. B. (1999). Cocaine: history, use, abuse. J R Soc Med, 92(8), 393-397.
PART VII: REFERENCES
77
Kelly, B. C., & Parsons, J. T. (2008). Predictors and comparisons of polydrug and non-
polydrug cocaine use in club subcultures. Am J Drug Alcohol Abuse, 34(6), 774-
781.
Khorana, N., Pullagurla, M. R., Young, R., & Glennon, R. A. (2004). Comparison of the
discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA)
and cocaine: asymmetric generalization. Drug Alcohol Depend, 74(3), 281-287.
Kimes, B. W., & Brandt, B. L. (1976). Properties of a clonal muscle cell line from rat heart.
Exp Cell Res, 98(2), 367-381.
King, V. L., Kidorf, M. S., Stoller, K. B., Carter, J. A., & Brooner, R. K. (2001). Influence of
antisocial personality subtypes on drug abuse treatment response. J Nerv Ment Dis,
189(9), 593-601.
Kintz, P., Sengler, C., Cirimele, V., & Mangin, P. (1997). Evidence of crack use by
anhydroecgonine methylester identification. Hum Exp Toxicol, 16(2), 123-127.
Kloner, R. A., Hale, S., Alker, K., & Rezkalla, S. (1992). The effects of acute and chronic
cocaine use on the heart. Circulation, 85(2), 407-419.
Kobayashi, T., Nishizawa, D., & Ikeda, K. (2011). Inhibition of g protein-activated inwardly
rectifying k channels by phencyclidine. Curr Neuropharmacol, 9(1), 244-246.
Koczor, C. A., Ludlow, I., Hight, R. S., 2nd, Jiao, Z., Fields, E., Ludaway, T., Lewis, W.
(2015). Ecstasy (MDMA) Alters Cardiac Gene Expression and DNA Methylation:
Implications for Circadian Rhythm Dysfunction in the Heart. Toxicol Sci, 148(1), 183-
191.
Koop, D. R., & Tierney, D. J. (1990). Multiple mechanisms in the regulation of ethanol-
inducible cytochrome P450IIE1. Bioessays, 12(9), 429-435.
Kosten, T. R., Kosten, T. A., McDougle, C. J., Hameedi, F. A., McCance, E. F., Rosen, M.
I., Price, L. H. (1996). Gender differences in response to intranasal cocaine
administration to humans. Biol Psychiatry, 39(2), 147-148.
LeDuc, B. W., Sinclair, P. R., Shuster, L., Sinclair, J. F., Evans, J. E., & Greenblatt, D. J.
(1993). Norcocaine and N-hydroxynorcocaine formation in human liver microsomes:
role of cytochrome P-450 3A4. Pharmacology, 46(5), 294-300.
LeDuc, B. W., Sinclair, P. R., Walton, H. S., Sinclair, J. F., Greenblatt, D. J., & Shuster, L.
(1994). Cocaine toxicity in cultured chicken hepatocytes: role of cytochrome P450.
Toxicol Appl Pharmacol, 125(2), 322-332.
Leri, F., Bruneau, J., & Stewart, J. (2003). Understanding polydrug use: review of heroin
and cocaine co-use. Addiction, 98(1), 7-22.
Li, A. P., Kaminski, D. L., & Rasmussen, A. (1995). Substrates of human hepatic
cytochrome P450 3A4. Toxicology, 104(1-3), 1-8.
PART VII: REFERENCES
78
Li, S. Y., Li, Q., Shen, J. J., Dong, F., Sigmon, V. K., Liu, Y., & Ren, J. (2006). Attenuation
of acetaldehyde-induced cell injury by overexpression of aldehyde dehydrogenase-
2 (ALDH2) transgene in human cardiac myocytes: role of MAP kinase signaling. J
Mol Cell Cardiol, 40(2), 283-294.
Lowry, O. H., Rosebrough, N. J., Farr, A. L., & Randall, R. J. (1951). Protein measurement
with the Folin phenol reagent. J Biol Chem, 193(1), 265-275.
Lukas, S. E., Sholar, M., Lundahl, L. H., Lamas, X., Kouri, E., Wines, J. D., Mendelson, J.
H. (1996). Sex differences in plasma cocaine levels and subjective effects after
acute cocaine administration in human volunteers. Psychopharmacology (Berl),
125(4), 346-354.
Maldonado, R. (1997). Participation of noradrenergic pathways in the expression of opiate
withdrawal: biochemical and pharmacological evidence. Neurosci Biobehav Rev,
21(1), 91-104.
Malison, R. T., Best, S. E., van Dyck, C. H., McCance, E. F., Wallace, E. A., Laruelle, M., .
. . Innis, R. B. (1998). Elevated striatal dopamine transporters during acute cocaine
abstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry, 155(6), 832-
834.
Marks, V., & Chapple, P. A. (1967). Hepatic dysfunction in heroin and cocaine users. Br J
Addict Alcohol Other Drugs, 62(1), 189-195.
Matthews, J. C., & Collins, A. (1983). Interactions of cocaine and cocaine congeners with
sodium channels. Biochem Pharmacol, 32(3), 455-460.
Maurer, H. H., Sauer, C., & Theobald, D. S. (2006). Toxicokinetics of drugs of abuse: current
knowledge of the isoenzymes involved in the human metabolism of
tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther Drug Monit,
28(3), 447-453.
McCance-Katz, E. F., Kosten, T. R., & Jatlow, P. (1998). Concurrent use of cocaine and
alcohol is more potent and potentially more toxic than use of either alone--a multiple-
dose study. Biol Psychiatry, 44(4), 250-259.
McCance, E. F., Price, L. H., Kosten, T. R., & Jatlow, P. I. (1995). Cocaethylene:
pharmacology, physiology and behavioral effects in humans. J Pharmacol Exp Ther,
274(1), 215-223.
Misra, A. L., Pontani, R. B., & Vadlamani, N. L. (1987). Stereospecific potentiation of opiate
analgesia by cocaine: predominant role of noradrenaline. Pain, 28(1), 129-138.
Moolchan, E. T., Cone, E. J., Wstadik, A., Huestis, M. A., & Preston, K. L. (2000). Cocaine
and metabolite elimination patterns in chronic cocaine users during cessation:
plasma and saliva analysis. J Anal Toxicol, 24(7), 458-466.
PART VII: REFERENCES
79
Morgan, A. E., Horan, B., Dewey, S. L., & Ashby, C. R., Jr. (1997). Repeated administration
of 3,4-methylenedioxymethamphetamine augments cocaine's action on dopamine
in the nucleus accumbens: a microdialysis study. Eur J Pharmacol, 331(1), R1-3.
Muller, C. P., Carey, R. J., Huston, J. P., & De Souza Silva, M. A. (2007). Serotonin and
psychostimulant addiction: focus on 5-HT1A-receptors. Prog Neurobiol, 81(3), 133-
178.
Myers, A. L., Williams, H. E., Kraner, J. C., & Callery, P. S. (2005). Identification of
anhydroecgonine ethyl ester in the urine of a drug overdose victim. J Forensic Sci,
50(6), 1481-1485.
Ndikum-Moffor, F. M., Schoeb, T. R., & Roberts, S. M. (1998). Liver toxicity from norcocaine
nitroxide, an N-oxidative metabolite of cocaine. J Pharmacol Exp Ther, 284(1), 413-
419.
Neri, M., Cerretani, D., Fiaschi, A. I., Laghi, P. F., Lazzerini, P. E., Maffione, A. B., Fineschi,
V. (2007). Correlation between cardiac oxidative stress and myocardial pathology
due to acute and chronic norepinephrine administration in rats. J Cell Mol Med,
11(1), 156-170.
Nicolas, J. M., Rubin, E., & Thomas, A. P. (1996). Ethanol and cocaine cause additive
inhibitory effects on the calcium transients and contraction in single cardiomyocytes.
Alcohol Clin Exp Res, 20(6), 1077-1082.
Niemela, O. (2007). Acetaldehyde adducts in circulation. Novartis Found Symp, 285, 183-
192; discussion 193-187.
Nott, M. W. (1968). Potentiation of morphine analgesia by cocaine in mice. Eur J Pharmacol,
5(1), 93-99.
O'Leary, M. E., & Hancox, J. C. (2010). Role of voltage-gated sodium, potassium and
calcium channels in the development of cocaine-associated cardiac arrhythmias. Br
J Clin Pharmacol, 69(5), 427-442.
Olszewski, D., Matias, J., Monshouwer, K., & Kokkevi, A. (2009). Polydrug use among 15-
to 16-year-olds: Similarities and differences in Europe. Drugs: Education,
Prevention and Policy.
Pakula, B., Macdonald, S., & Stockwell, T. (2009). Settings and functions related to
simultaneous use of alcohol with marijuana or cocaine among clients in treatment
for substance abuse. Subst Use Misuse, 44(2), 212-226.
Pakula, B., Macdonald, S., Stockwell, T., & Sharma, R. (2009). Simulatneous use of alcohol
and cocaine: A qualitative investigation. Journal of Substance USe, 14(2), 101-112.
Panos, J. J., & Baker, L. E. (2010). An in vivo microdialysis assessment of concurrent
MDMA and cocaine administration in Sprague-Dawley rats. Psychopharmacology
(Berl), 209(1), 95-102.
PART VII: REFERENCES
80
Pattison, L. P., McIntosh, S., Budygin, E. A., & Hemby, S. E. (2012). Differential regulation
of accumbal dopamine transmission in rats following cocaine, heroin and speedball
self-administration. J Neurochem, 122(1), 138-146.
Pattison, L. P., McIntosh, S., Sexton, T., Childers, S. R., & Hemby, S. E. (2014). Changes
in dopamine transporter binding in nucleus accumbens following chronic self-
administration cocaine: heroin combinations. Synapse, 68(10), 437-444.
Pellinen, P., Honkakoski, P., Stenback, F., Niemitz, M., Alhava, E., Pelkonen, O., Pasanen,
M. (1994). Cocaine N-demethylation and the metabolism-related hepatotoxicity can
be prevented by cytochrome P450 3A inhibitors. Eur J Pharmacol, 270(1), 35-43.
Pellinen, P., Kulmala, L., Konttila, J., Auriola, S., Pasanen, M., & Juvonen, R. (2000). Kinetic
characteristics of norcocaine N-hydroxylation in mouse and human liver
microsomes: involvement of CYP enzymes. Arch Toxicol, 74(9), 511-520.
Pellinen, P., Stenback, F., Kojo, A., Honkakoski, P., Gelboin, H. V., & Pasanen, M. (1996).
Regenerative changes in hepatic morphology and enhanced expression of
CYP2B10 and CYP3A during daily administration of cocaine. Hepatology, 23(3),
515-523.
Perez-Reyes, M. (1993). Subjective and cardiovascular effects of cocaethylene in humans.
Psychopharmacology (Berl), 113(1), 144-147.
Perez-Reyes, M., & Jeffcoat, A. R. (1992). Ethanol/cocaine interaction: cocaine and
cocaethylene plasma concentrations and their relationship to subjective and
cardiovascular effects. Life Sci, 51(8), 553-563.
Perez-Reyes, M., Jeffcoat, A. R., Myers, M., Sihler, K., & Cook, C. E. (1994). Comparison
in humans of the potency and pharmacokinetics of intravenously injected
cocaethylene and cocaine. Psychopharmacology (Berl), 116(4), 428-432.
Perino, L. E., Warren, G. H., & Levine, J. S. (1987). Cocaine-induced hepatotoxicity in
humans. Gastroenterology, 93(1), 176-180.
Pilgrim, J. L., Woodford, N., & Drummer, O. H. (2013). Cocaine in sudden and unexpected
death: a review of 49 post-mortem cases. Forensic Sci Int, 227(1-3), 52-59.
Poet, T. S., Brendel, K., & Halpert, J. R. (1994). Inactivation of cytochromes P450 2B
protects against cocaine-mediated toxicity in rat liver slices. Toxicol Appl Pharmacol,
126(1), 26-32.
Poet, T. S., McQueen, C. A., & Halpert, J. R. (1996). Participation of cytochromes P4502B
and P4503A in cocaine toxicity in rat hepatocytes. Drug Metab Dispos, 24(1), 74-
80.
Politi, L., Zucchella, A., Morini, L., Stramesi, C., & Polettini, A. (2007). Markers of chronic
alcohol use in hair: comparison of ethyl glucuronide and cocaethylene in cocaine
users. Forensic Sci Int, 172(1), 23-27.
PART VII: REFERENCES
81
Pontes, H., de Pinho, P. G., Fernandes, E., Branco, P. S., Ferreira, L. M., Carmo, H.,
Bastos, M. L. (2010). Metabolic interactions between ethanol and MDMA in primary
cultured rat hepatocytes. Toxicology, 270(2-3), 150-157.
Restrepo, C. S., Rojas, C. A., Martinez, S., Riascos, R., Marmol-Velez, A., Carrillo, J., &
Vargas, D. (2009). Cardiovascular complications of cocaine: imaging findings.
Emerg Radiol, 16(1), 11-19.
Reyes, S., Kane, G. C., Zingman, L. V., Yamada, S., & Terzic, A. (2009). Targeted
disruption of K(ATP) channels aggravates cardiac toxicity in cocaine abuse. Clin
Transl Sci, 2(5), 361-365.
Rhodes, T., Briggs, D., Kimber, J., Jones, S., & Holloway, G. (2007). Crack-heroin speedball
injection and its implications for vein care: qualitative study. Addiction, 102(11),
1782-1790.
Rothman, R. B., & Baumann, M. H. (2003). Monoamine transporters and psychostimulant
drugs. Eur J Pharmacol, 479(1-3), 23-40.
Sardao, V. A., Oliveira, P. J., Holy, J., Oliveira, C. R., & Wallace, K. B. (2007). Vital imaging
of H9c2 myoblasts exposed to tert-butylhydroperoxide--characterization of
morphological features of cell death. BMC Cell Biol, 8, 11.
Satran, A., Bart, B. A., Henry, C. R., Murad, M. B., Talukdar, S., Satran, D., & Henry, T. D.
(2005). Increased prevalence of coronary artery aneurysms among cocaine users.
Circulation, 111(19), 2424-2429.
Schilstrom, B., Yaka, R., Argilli, E., Suvarna, N., Schumann, J., Chen, B. T., . . . Bonci, A.
(2006). Cocaine enhances NMDA receptor-mediated currents in ventral tegmental
area cells via dopamine D5 receptor-dependent redistribution of NMDA receptors. J
Neurosci, 26(33), 8549-8558.
Schmid, Y., Vizeli, P., Hysek, C. M., Prestin, K., Meyer Zu Schwabedissen, H. E., & Liechti,
M. E. (2016). CYP2D6 function moderates the pharmacokinetics and
pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study
in healthy individuals. Pharmacogenet Genomics, 26(8), 397-401.
Shen, H., He, M. M., Liu, H., Wrighton, S. A., Wang, L., Guo, B., & Li, C. (2007).
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1,
CYP2D6.10, and CYP2D6.17. Drug Metab Dispos, 35(8), 1292-1300.
Shenouda, S. K., Lord, K. C., McIlwain, E., Lucchesi, P. A., & Varner, K. J. (2008). Ecstasy
produces left ventricular dysfunction and oxidative stress in rats. Cardiovasc Res,
79(4), 662-670.
Shimada, A., Tsuda, T., & Yanagita, T. (1988). Mode of potentiating action of cocaine in
morphine analgesia. Jpn J Pharmacol, 48(2), 185-193.
PART VII: REFERENCES
82
Sierra, V., Duttaroy, A., Lutfy, K., Candido, J., Billings, B., Zito, S. W., & Yoburn, B. C.
(1992). Potentiation of opioid analgesia by cocaine: the role of spinal and
supraspinal receptors. Life Sci, 50(8), 591-597.
Smith, A. C., Freeman, R. W., & Harbison, R. D. (1981). Ethanol enhancement of cocaine-
induced hepatotoxicity. Biochem Pharmacol, 30(5), 453-458.
Sobel, B. F., & Riley, A. L. (1999). The interaction of cocaethylene and cocaine and of
cocaethylene and alcohol on schedule-controlled responding in rats.
Psychopharmacology (Berl), 145(2), 153-161.
Song, B.-J., Moon, K.-H., Upreti, V. V., Eddington, N. D., & Lee, I. J. (2010). Mechanisms
of MDMA (Ecstasy)-Induced Oxidative Stress, Mitochondrial Dysfunction, and
Organ Damage. Current pharmaceutical biotechnology, 11(5), 434-443.
Sora, I., Hall, F. S., Andrews, A. M., Itokawa, M., Li, X. F., Wei, H. B., Uhl, G. R. (2001).
Molecular mechanisms of cocaine reward: combined dopamine and serotonin
transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci U S
A, 98(9), 5300-5305.
Starosciak, A. K., Zakharova, E., Stagg, M., Matos, J., & Izenwasser, S. (2012). Differential
alteration of the effects of MDMA (ecstasy) on locomotor activity and cocaine
conditioned place preference in male adolescent rats by social and environmental
enrichment. Psychopharmacology (Berl), 224(1), 101-108.
Sultana, R., Bhupanapadu Sunkesula, S. R., Sharma, V., Reddanna, P., & Babu, P. P.
(2005). Formation of acetaldehyde adducts of glutathione S-transferase A3 in the
liver of rats administered alcohol chronically. Alcohol, 35(1), 57-66.
Tashkin, D. P., Kleerup, E. C., Koyal, S. N., Marques, J. A., & Goldman, M. D. (1996). Acute
effects of inhaled and i.v. cocaine on airway dynamics. Chest, 110(4), 904-910.
Thompson, M. L., Shuster, L., & Shaw, K. (1979). Cocaine-induced hepatic necrosis in
mice--the role of cocaine metabolism. Biochem Pharmacol, 28(15), 2389-2395.
Turrens, J. F. (2003). Mitochondrial formation of reactive oxygen species. J Physiol, 552(Pt
2), 335-344.
Uszenski, R. T., Gillis, R. A., Schaer, G. L., Analouei, A. R., & Kuhn, F. E. (1992). Additive
myocardial depressant effects of cocaine and ethanol. Am Heart J, 124(5), 1276-
1283.
Valente, M. J., Araujo, A. M., Bastos Mde, L., Fernandes, E., Carvalho, F., Guedes de
Pinho, P., & Carvalho, M. (2016). Editor's Highlight: Characterization of
Hepatotoxicity Mechanisms Triggered by Designer Cathinone Drugs (beta-Keto
Amphetamines). Toxicol Sci, 153(1), 89-102.
PART VII: REFERENCES
83
Valente, M. J., Carvalho, F., Bastos, M., de Pinho, P. G., & Carvalho, M. (2012).
Contribution of oxidative metabolism to cocaine-induced liver and kidney damage.
Curr Med Chem, 19(33), 5601-5606.
Van der Poel, A., Rodenburg, G., Dijkstra, M., Stoele, M., & Van de Mheen, D. (2009).
Trends, motivations and settings of recreational cocaine use by adolescents and
young adults in the Netherlands. Int J Drug Policy, 20(2), 143-151.
Vendemiale, G., Grattagliano, I., Altomare, E., Serviddio, G., Portincasa, P., Prigigallo, F.,
& Palasciano, G. (2001). Mitochondrial oxidative damage and myocardial fibrosis in
rats chronically intoxicated with moderate doses of ethanol. Toxicol Lett, 123(2-3),
209-216.
Volkow, N. D. (2009). Cocaine abuse and addiction. NIH publication.  Retrieved 25 January,
2015, from http://www.drugabuse.gov/publications/research-reports/cocaine/what-
cocaine
Volkow, N. D., Fowler, J. S., & Wang, G. J. (2003). The addicted human brain: insights from
imaging studies. J Clin Invest, 111(10), 1444-1451.
Volkow, N. D., Fowler, J. S., Wang, G. J., & Swanson, J. M. (2004). Dopamine in drug abuse
and addiction: results from imaging studies and treatment implications. Mol
Psychiatry, 9(6), 557-569.
Ward, S. J., Morgan, D., & Roberts, D. C. (2005). Comparison of the reinforcing effects of
cocaine and cocaine/heroin combinations under progressive ratio and choice
schedules in rats. Neuropsychopharmacology, 30(2), 286-295.
Welder, A. A., Smith, M. A., Ramos, K., & Acosta, D. (1988). Cocaine-induced cardiotoxicity
in vitro. Toxicol In Vitro, 2(3), 205-213.
Williams, H., Dratcu, L., Taylor, R., Roberts, M., & Oyefeso, A. (1998). "Saturday night
fever": ecstasy related problems in a London accident and emergency department.
J Accid Emerg Med, 15(5), 322-326.
Winstock, A. R., Griffiths, P., & Stewart, D. (2001). Drugs and the dance music scene: a
survey of current drug use patterns among a sample of dance music enthusiasts in
the UK. Drug Alcohol Depend, 64(1), 9-17.
Wojtczak, L., Teplova, V. V., Bogucka, K., Czyz, A., Makowska, A., Wieckowski, M. R., . . .
Evtodienko, Y. V. (1999). Effect of glucose and deoxyglucose on the redistribution
of calcium in ehrlich ascites tumour and Zajdela hepatoma cells and its
consequences for mitochondrial energetics. Further arguments for the role of Ca(2+)
in the mechanism of the crabtree effect. Eur J Biochem, 263(2), 495-501.
Xu, W., Flick, T., Mitchel, J., Knowles, C., & Ault, K. (1999). Cocaine effects on
immunocompetent cells: an observation of in vitro cocaine exposure. Int J
Immunopharmacol, 21(7), 463-472.
PART VII: REFERENCES
84
Yao, D., Shi, X., Wang, L., Gosnell, B. A., & Chen, C. (2013). Characterization of differential
cocaine metabolism in mouse and rat through metabolomics-guided metabolite
profiling. Drug Metab Dispos, 41(1), 79-88.
Yuan, C., & Acosta, D., Jr. (2000). Effect of cocaine on mitochondrial electron transport
chain evaluated in primary cultures of neonatal rat myocardial cells and in isolated
mitochondrial preparations. Drug Chem Toxicol, 23(2), 339-348.
Zaragoza, A., Diez-Fernandez, C., Alvarez, A. M., Andres, D., & Cascales, M. (2001).
Mitochondrial involvement in cocaine-treated rat hepatocytes: effect of N-
acetylcysteine and deferoxamine. Br J Pharmacol, 132(5), 1063-1070.
Zhan, M., Hou, S., Zhan, C. G., & Zheng, F. (2014). Kinetic characterization of high-activity
mutants of human butyrylcholinesterase for the cocaine metabolite norcocaine.
Biochem J, 457(1), 197-206.
